etoposide has been researched along with Adenocarcinoma in 479 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 80 (16.70) | 18.7374 |
| 1990's | 202 (42.17) | 18.2507 |
| 2000's | 124 (25.89) | 29.6817 |
| 2010's | 69 (14.41) | 24.3611 |
| 2020's | 4 (0.84) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, DT; Clement, JJ; Klein, LL; McDonald, EJ; Plattner, JJ; Yeung, CM | 1 |
| Bisagni, E; Croisy, A; Janin, YL; Riou, JF | 1 |
| Bastow, KF; Cheng, HH; Ito, J; Lee, KH; Luo, TY; Nakanishi, Y; Tachibana, Y; Wang, HK; Xu, Z | 1 |
| Chen, JY; Cheng, KF; Ding, J; Meng, LH; Qin, GW; Yu, BW; Zhou, TX | 1 |
| Béhard, A; Collignon, F; Darro, F; Decaestecker, C; Frydman, A; Guillaumet, G; Joseph, B; Kiss, R; Lesur, B | 1 |
| Ashok Kumar, B; Gururaj, S; Lingaiah, BP; Narsaiah, B; Parthasarathy, T; Shireesha, B; Sridhar, B; Yakaiah, T | 1 |
| Chen, SB; Gu, LQ; Huang, SL; Huang, ZH; Huang, ZS; Li, D; Ou, JB; Ou, TM; Shen, LL; Tan, JH; Wu, WB | 1 |
| Andricopulo, AD; Beraldo, H; Da Silva, JG; Daghestani, H; Day, BW; Dos Santos, RG; Lessa, JA; Mendes, IC; Pesquero, JL; Rocha, WR; Salum, LB; Soares, MA; Vogt, A | 1 |
| Hosono, M; Namikoshi, M; Rotinsulu, H; Sumilat, DA; Tatsuta, T; Wewengkang, DS; Yamazaki, H | 1 |
| Chen, Y; Han, B; Hu, M; Qian, F; Wang, Y; Yang, Z; Zhang, W; Zhang, Y | 1 |
| Hara, S; Hata, A; Komatsu, M; Ninomaru, T | 1 |
| Bal, A; Gupta, N; Gupta, P; Khosla, D; Shastri, M; Singh, N; Srinivasan, R | 1 |
| Alonso-Gordoa, T; Brabander, T; Cadiot, G; Caminoa, A; Capdevila, J; Chakrabarty, B; Couvelard, A; Cros, J; de Mestier, L; García Gómez-Muriel, MI; Garcia-Alvarez, A; Hernando, J; Kats-Ugurlu, G; Lamarca, A; Landolfi, S; Manoharan, P; Pavel, ME; Perrier, M; Ronot, M; Van Velthuysen, MF; Walenkamp, AM; Zandee, W | 1 |
| Chen, L; Cheng, L; Liang, X; Liu, L; Ma, C; Wu, X; Xiao, L; Xu, Q; Zhang, L | 1 |
| Cha, HJ; Go, YH; Hong, SK; Kwon, OS; Kwon, SJ; Oh, E | 1 |
| Carew, M; Jaksevicius, A; Mistry, C; Modjtahedi, H; Opara, EI | 1 |
| Allan, E; Hanna, F; Khalafallah, AA; Prakash, A | 1 |
| Gan, H; Pei, Y; Shi, Z; Sun, B; Zhu, H | 1 |
| Annala, M; Beltran, H; Chedgy, EC; Chi, KN; Donoghue, AJ; Fazli, L; Herberts, C; Hurtado-Coll, A; Konomura, S; Liew, J; Parimi, S; Ritch, E; Sboner, A; Sigouros, M; Struss, W; Vandekerkhove, G; Vergidis, J; Wyatt, AW | 1 |
| Amemiya, K; Hirotsu, Y; Iijima, Y; Kakizaki, Y; Kobayashi, Y; Miyashita, Y; Mochizuki, H; Omata, M; Oyama, T; Tsutsui, T; Uchida, Y | 1 |
| Ben Mrad, M; Chauleur, C; de Laroche, G; Espenel, S; Garcia, MA; Guy, JB; Langrand-Escure, J; Magné, N; Moreno-Acosta, P; Rancoule, C; Trone, JC; Vallard, A | 1 |
| Aldrich, JD; Overman, MJ; Raghav, KPS; Varadhachary, GR; Wolff, RA | 1 |
| Bando-Polaino, I; Cabezas-Camarero, S; de la Orden García, V; Díaz-Rubio, E; García-Barberán, V; Llovet García, P; Mediero-Valeros, B; Merino Menéndez, S; Pérez-Segura, P; Subhi-Issa, AI | 1 |
| Lee, DW; Lee, HN; Lee, JW; Lee, KH; Park, JS; Park, ST | 1 |
| Jamil, K; Naidu Madireddy, UR; Natukula, K; Pingali, UR; Suresh Attili, VS | 1 |
| Argiris, A; Gooding, WE; McLaughlin, B; Schmitz, JC; Siegfried, JM; Socinski, MA; Tarhini, AA; Zahoor, H | 1 |
| Fan, D; Hu, Y; Li, S; Xiong, D; Yagüe, E; Yan, C; Yang, M; Zhang, Y; Zhou, Y | 1 |
| Blower, PJ; Diocou, S; Fruhwirth, GO; Mullen, GE; Ng, T | 1 |
| Ichi, T; Ishikawa, K; Kawabata, T; Kawasaki, H; Taira, N; Yohena, T | 1 |
| Batus, M; Bonomi, P; Dandekar, VK; Fidler, MJ; Kiel, K; Sher, DJ; Young, J | 1 |
| Asamura, H; Fujiwara, Y; Horinouchi, H; Kanda, S; Kitazono, S; Mizugaki, H; Nokihara, H; Tamura, T; Tanaka, A; Tsuta, K; Yagishita, S; Yamamoto, N | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Han, J; Ji, JH; Kim, KM; Park, K; Sun, JM | 1 |
| Banin, VV; Borisova, LM; Fedotcheva, TA; Kiseleva, MP; Rzheznikov, VM; Semeĭkin, AV; Shimanovskiĭ, NL; Shirokikh, KE; Smirnova, zS; Tolkachev, VN | 1 |
| Kadalayil, L; KhoshZaban, M; Kuku, S; Ledermann, J; Loddo, M; McCormack, M; Proctor, I | 1 |
| Du, XL; Li, HQ; Lu, CH; Pan, CX; Sheng, XG; Wang, C; Yin, YJ | 1 |
| Choi, KH; Hwang, KE; Jeong, ET; Jung, JW; Kim, HR; Oh, SJ; Park, MJ; Shon, YJ | 1 |
| Bonventre, JV; Ichimura, T; Ikemi, Y; Kim, YH; Masuda, S; Matsubara, K; Mishima, M; Ozawa, A; Sato, T; Shinke, H; Togashi, Y | 1 |
| Shiau, AL; Shieh, GS; Su, BH; Tseng, YL; Wu, CL | 1 |
| Hur, GY; Kang, EJ; Kang, KH; Kim, JS; Lee, SY; Min, KH; Oh, SC; Seo, JH; Shim, JJ | 1 |
| Choe, AR; Choi, JE; Lee, KE; Nam, EM; Park, H; Yoon, SE | 1 |
| Akyuz, MD; Büttner, R; Erkel, M; Florin, A; Fritz, C; Jokić, M; Klümper, N; Kümpers, C; Maintz, D; Michels, S; Nowak, M; Offermann, A; Ozretić, L; Perner, S; Persigehl, T; Reinhardt, HC; Riabinska, A; Rinneburger, M; Schmitt, A; Schumacher, B; Spiro, J; Thomale, J; Vlašić, I; Vogel, W; Welcker, D; Wittersheim, M; Wolf, J | 1 |
| Hosoda, Y; Imamura, M; Kawai, J; Kiyochi, H; Komoto, I; Nishiyama, K; Ogura, N; Okabe, A; Oshima, Y; Sugimoto, T; Taki, Y; Tsunekawa, S | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Han, J; Hwang, IG; Kim, J; Lee, S; Park, BB; Park, K; Shim, YM | 1 |
| Fujii, Y; Fukui, I; Ishikawa, Y; Kawakami, S; Komai, Y; Okubo, Y; Takeshita, H; Tatokoro, M; Yamamoto, S; Yonese, J | 1 |
| Kinukawa, N; Kunoki, N; Moriyama, M; Nishiyama, R; Ogawa, M; Ogihara, A; Oonishi, M; Ryuzaki, H; Sou, K; Tanaka, N; Uno, A; Yamamoto, T | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Altevogt, P; Fölsch, UR; Gast, D; Geismann, C; Kötteritzsch, J; Kruse, ML; Schäfer, H; Sebens Müerköster, S | 1 |
| Coosemans, W; De Leyn, P; Decaluwé, H; Decker, G; Lerut, T; Lievens, Y; Moons, J; Nafteux, P; Van Raemdonck, D; Vansteenkiste, J | 1 |
| Druck, P; Gupta, P; Iwamoto, C; Mesa, H; Niehans, GA; Rawal, A; Rezcallah, A | 1 |
| Drew, PA; Jamieson, GG; Liu, JF; Wu, TC; Zhu, GJ | 1 |
| Bao, QL; Chen, P; Dai, CH; Li, J; Li, XQ | 1 |
| Berek, JS; Brady, M; Hutson, A; Markman, M | 1 |
| Lou, F; Pan, HM; Zhu, YH | 1 |
| Chen, X; Huang, Q; Li, C; Li, J; Liu, X; Qiu, Z; Tian, Y; Wang, Y; Wolf, F; Xie, K; Xu, P; Zhang, D | 1 |
| Alici, S; Benekli, M; Buyukberber, S; Camci, C; Coskun, U; Dane, F; Gumus, M; Kalender, ME; Kaya, AO; Ozturk, B; Sevinc, A; Uncu, D; Yaman, E; Yildiz, R | 1 |
| Fujii, M; Funada, T; Kaiga, T; Kanamori, N; Kochi, M; Takahashi, T; Takayama, T | 1 |
| Allegro, R; Altieri, V; De Grande, G; Falsaperla, M; Melloni, D; Morgia, G; Napoli, M; Serretta, V; Siragusa, A | 1 |
| Baldi, A; Beleford, D; Boccellino, M; Liu, Z; Maguire, J; Molina, J; Quagliuolo, L; Rattan, R; Shridhar, V; Staub, J | 1 |
| Chen, XM; Huang, ZG; Wang, ZR; Zhang, DW; Zhang, X; Zhu, FS | 1 |
| Bazin, IS; Fedyanin, MY; Garin, AM; Kanagavel, D; Narimanov, MN; Pokataev, IA; Tjulandin, SA; Tryakin, AA; Yakovleva, ES | 1 |
| García-López, P; Guerrero-Vargas, NN; Jurado, R; Virto-Aguilar, J | 1 |
| Bobrzynski, L; Dadan, J; Drews, M; Jedrys, J; Jeziorski, A; Kolodziejczyk, P; Krawczyk, M; Kulig, J; Popiela, T; Sierzega, M; Starzynska, T; Wallner, G | 1 |
| Feigenberg, S; Huang, CH; Jotte, RM; Langer, CJ; Monberg, MJ; Movsas, B; Obasaju, CK; Ross, HJ; Wang, L; Xu, F | 1 |
| Abbruzzese, A; Addeo, R; Caraglia, M; Carbone, SF; Correale, P; Francini, G; Gotti, G; Licchetta, A; Martellucci, I; Migali, C; Remondo, C; Ricci, V; Rotundo, MS; Sperlongano, P; Tagliaferri, P; Tassone, P; Volterrani, L | 1 |
| Gupta, A; Mittal, B; Natu, SM; Negi, MP; Prasad, R; Srivastava, AN; Srivastava, S | 1 |
| Bai, T; Tanaka, T; Yukawa, K | 1 |
| Fujimoto, T; Kumagai, S; Kurachi, H; Mizunuma, H; Nakahara, K; Nishiyama, H; Omi, H; Shoji, T; Sugiyama, T; Takano, T; Takatori, E; Tase, T; Yaegashi, N; Yokoyama, Y; Yoshizaki, A | 1 |
| Lee, DW; Lee, HN; Lee, KH; Lee, YS; Park, EK; Park, JS | 1 |
| Golshayan, A; Harrer, GW; Hussain, MH; Mills, GM; Smith, DC; Tangen, CM; Thompson, IM; Van Veldhuizen, PJ; Vogelzang, NJ | 1 |
| Brammer, JE; Lulla, P; Lynch, GR | 1 |
| Beuzeboc, P; Culine, S; Deplanque, G; Droz, JP; Fargeot, P; Ferlay, C; Fléchon, A; Gravis, G; Joly, F; Oudard, S; Perol, D; Pouessel, D; Priou, F; Zanetta, S | 1 |
| Cegovnik, U; Kern, I; Korošec, P; Košnik, M; Rijavec, M; Silar, M; Triller, N | 1 |
| Abbruzzese, A; Addeo, R; Apollinari, S; Basile, A; Bestoso, E; Botta, C; Caraglia, M; Correale, P; Gotti, G; Lamberti, M; Licchetta, A; Luzzi, L; Martellucci, I; Misso, G; Pagliuchi, M; Romano, O; Rotundo, MS; Tagliaferri, P | 1 |
| Harada, T; Itamochi, H; Kigawa, J; Naniwa, J; Nonaka, M; Oishi, T; Sato, S; Shimada, M; Terakawa, N; Uegaki, K | 1 |
| Blagden, S; Gabra, H; Graham, J; Sharma, R | 1 |
| Montes-Mollón, MÁ; Paz Moreno-Arrones, J | 1 |
| Bollag, WB; Liu, F; Liu, K; Liu, Q; Robertson, K; Wu, P; Yang, D | 1 |
| Chen, MC; Lee, KH; Li, TK; Pan, SL; Shi, Q; Teng, CM; Xiao, Z | 1 |
| Chen, CP; Jablons, DM; Jahan, TM; Weinberg, VK; Yom, SS | 1 |
| Balashova, EE; Dashtiev, MI; Lokhov, PG | 1 |
| Bellot, GL; Koh, D; Tan, WH; Tay, LL; Wang, X | 1 |
| Korbakis, D; Scorilas, A | 1 |
| DU, JP; Han, Y; Li, SJ; Wang, JH; Wang, ZH; Wu, ZT; Yang, XY; Zhai, LP | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Behrens, C; Correa, AM; Erasmus, JJ; Kalhor, N; Kim, ES; Lee, JJ; Pataer, A; Raso, MG; Roth, JA; Stewart, DJ; Swisher, SG; Vaporciyan, AA; Wistuba, II | 1 |
| Comans, EF; Hartemink, KJ; Paul, MA; Phernambucq, EC; Postmus, PE; Senan, S; Smit, EF | 1 |
| Eitaki, M; Inanami, O; Meike, S; Yamamori, T; Yasui, H | 1 |
| Amato, B; Cardin, F; Lorenzetti, R; Martella, B; Militello, C; Terranova, C | 1 |
| Chen, W; He, Y; Peng, J; Song, W; Zhang, S | 1 |
| Choi, HG; Kim, SH; Lee, MG; Lim, SJ; Yang, SH | 1 |
| Fragoulis, EG; Korbakis, D; Scorilas, A | 1 |
| Jeremić, B; Miličić, B; Milisavljević, S | 1 |
| Araki, H; Kato, T; Miwa, Y; Moriwaki, H; Nagaki, M; Naito, T; Uematsu, T; Yasuda, I | 1 |
| Boldt, S; Kolch, W; Weidle, UH | 1 |
| Gennatas, K; Kosmas, C; Kouraklis, G; Margaris, E; Papastratis, G; Rokana, S; Skopelitis, E; Tsavaris, N; Vadiaka, M; Xila, V; Zografos, G | 1 |
| Krüger, I; Lindenfelser, R; Scherwitz, P | 1 |
| Dimtchev, A; Dritschilo, A; Jung, M; Rosenthal, D; Smulson, M; Soldatenkov, V; Trofimova, I | 1 |
| Aydingöz, U; Ayhan, A; Erman, M; Güler, N; Karaoğlu, A; Oksüzoğlu, B | 1 |
| Hamano, K; Hirohata, S; Inoue, H; Kawaguchi, K; Maeda, T; Matsumoto, I; Nakashima, T; Niki, T; Nishisaki, H; Okutani, T; Sashikata, T; Yasutake, K | 1 |
| Bar Sela, G; Gaitini, D; Haim, N; Steiner, M; Tsalic, M | 1 |
| Chang, H; Hsien Lee, Y; Lee, CC; Lin, S; Shyu, KG; Tsai, SC; Wang, BW | 1 |
| Cannon, MW; Jones, D; Kuebler, JP; Lee, SJ; Logothetis, CJ; Millikan, R; Thall, PF; Wade, J | 1 |
| Lee, HW; Lee, SJ; Lee, SS; Um, HD | 1 |
| Kamata, J; Kitoh, K; Kotake, Y; Koyanagi, N; Nagasu, T; Nakamura, K; Niijima, J; Okada, T; Sugumi, H; Taniguchi, T; Uenaka, T; Yamaguchi, A; Yoshimatsu, K; Yoshino, H | 1 |
| Blessing, JA; Buller, RE; Mannel, RS; Rose, PG; Webster, KD | 1 |
| Arlt, A; Fölsch, UR; Gehrz, A; Kruse, ML; Müerköster, S; Schäfer, H; Vorndamm, J | 1 |
| Huang, J; Jiao, SC; Lu, SX; Sun, Y | 1 |
| Chay, CH; Dunn, RL; Esper, P; Fardig, J; Olson, K; Pienta, KJ; Smith, DC | 1 |
| Bar-Sela, G; Gaitini, D; Haim, N; Steiner, M; Tsalic, M | 1 |
| Ayuso, MJ; Cortés, F; López-Lázaro, M; Martín-Cordero, C; Navarro, E; Palma De La Peña, N; Pastor, N; Toro, MV | 1 |
| Hoffarth, S; Huber, C; Milosevic, J; Schuler, M | 1 |
| Einhorn, LH; Foster, RS; Henley, JD; Sheski, FD | 1 |
| Chin, K; Furuta, N; Hatake, K; Itoh, Y; Mishima, Y; Mizunuma, N; Nagasaki, E; Shinozaki, E; Takahashi, S; Terui, Y; Tokutome, N; Usui, N | 1 |
| Butts, JA; Greco, FA; Hainsworth, JD; Meluch, AA; Morrissey, LH; Raefsky, EL; Steis, RG | 1 |
| Coleman, TA; Dainer, P; Hamill, RL; Redger, CD | 1 |
| Carlson, RW; Grekowicz, A; Hartman, AR; Lum, BL; Schurman, C; Shapiro, R; Sikic, BI; Stockdale, FE | 1 |
| Alamanis, C; Constantinidis, C; Deliveliotis, C; Dimopoulos, MA; Giannopoulos, A; Gika, D; Kiamouris, C; Koutsilieris, M; Zervas, A | 1 |
| Burholt, DR; Donovan, M; George, LD; Kornblith, PL; Marsh, JW | 1 |
| Richter, P; Solecki, R; Szura, M; Zajac, A | 1 |
| Abker, S; Bosse, U; Junker, K; Klinke, F; Müller, KM; Thomas, M | 1 |
| Nishiura, K; Obata, H; Okugawa, T; Tabata, T; Tanaka, K; Toyoda, N; Yanoh, K | 1 |
| Dong, M; Feng, FY; Fu, M; Liang, X; Lin, C; Lu, HY; Wu, M; Zha, YY; Zhang, XY | 1 |
| Jothy, S; Lakshman, M; Rubenthiran, U; Subramaniam, V | 1 |
| Fujiki, H; Harada, S; Imura, K; Itoh, T; Kimura, T; Naito, K; Nomura, K; Sonoda, Y; Taniwaki, M; Ueda, Y; Yamagishi, H | 1 |
| Fujisawa, M; Hara, I; Kamidono, S; Kanomata, N; Kawabata, G; Kumano, Y; Takeda, M; Tanaka, K | 1 |
| Bélanger, MM; Couet, J; Gaudreau, M; Roussel, E | 1 |
| Albregts, M; Crezee, H; Fockens, P; González González, D; Hulshof, MC; Richel, DJ; van Dijk, JD; van Lanschot, JJ; Zum Vörde Sive Vörding, PJ | 1 |
| Barone, C; Basso, M; Brunetti, IM; Cassano, A; D'Ugo, D; Longo, R; Persiani, R; Picciocchi, A; Pozzo, C; Schinzari, G | 1 |
| Enomoto, Y; Hatta, Y; Horie, T; Sawada, U; Takahashi, M; Takahashi, N | 1 |
| Hara, K; Iwasaka, T | 1 |
| Roemer, K; Wagner, S | 1 |
| Eimermacher, A; Flieger, D; Galle, PR; Geer, T; Gracien, E; Heike, M; Höhler, T; Junginger, T; Menges, M; Moehler, M; Siebler, J; Wein, A | 1 |
| Keefe, D; Myers, M; Olver, I | 1 |
| Chak, K; Chan, AT; Lam, KC; Lee, C; Mok, TS; Wong, H; Yeo, W; Yim, AP; Zee, B; Zhang, L | 1 |
| Asamura, H; Kodama, T; Kunitoh, H; Matsuno, Y; Ohe, Y; Saijo, N; Sekine, I; Takei, H; Tamura, T; Tsuchiya, R; Yamamoto, N; Yamazaki, S | 1 |
| Ariyoshi, Y; Fukuda, Y; Fukuoka, M; Isobe, T; Katakami, N; Komuta, K; Kudoh, S; Nakamura, S; Nakano, T; Takada, M; Takada, Y | 1 |
| Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC | 1 |
| Hatashita, M; Hayashi, S; Jin, ZH; Kano, E; Matsumoto, H; Shioura, H | 1 |
| Chang, WH; Chen, YJ; Liao, HF; Lin, CC; Lin, SC; Liu, CY; Shih, SC; Wang, TE; Yang, YC | 1 |
| Chimenti, D; Iorio, M; Maurich, T; Turchi, G | 1 |
| Cho, EK; Heo, DS; Jung, KH; Kim, JH; Kim, SY; Kim, YH; Lim, HY; Park, BJ; Park, K; Ryoo, BY; Suh, CW | 1 |
| Antic, N; de Lanerolle, P; Gu, LZ; Hu, WY; Mehta, R; Turner, JR | 1 |
| Balan, KV; Dimas, K; Han, Z; Pantazis, P; Sitaras, NM; Wyche, JH | 1 |
| Bogdanos, J; Dimopoulos, P; Dimopoulos, T; Halapas, A; Karamanolakis, D; Katopodis, H; Koutsilieris, M; Lembessis, P; Milathianakis, C; Papageorgiou, E; Pissimissis, N; Pitulis, N; Sourla, A; Tenta, R | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Venkatraman, G | 1 |
| Altevogt, P; Debus, MA; Fölsch, UR; Grossmann, M; Kappes, H; Klöppel, G; Kötteritzsch, J; Leisner, D; Schäfer, H; Sebens Müerköster, S; Sipos, B; Werbing, V; Witt, M | 1 |
| Cai, Y; Wang, WL; Xu, B; Zhang, SW; Zhu, GY | 1 |
| Doba, S; Funaki, K; Kawashima, A; Kiriyama, M; Kita, T; Kojima, Y; Kurosaka, Y; Michiwa, Y; Sasaki, S; Takekawa, S; Tamura, M | 1 |
| Bradford, AP; Haughian, JM; Jackson, TA; Koterwas, DM | 1 |
| Orzechowski, A; Pajak, B | 1 |
| Kenna, T; Mattarollo, SR; Nicol, AJ; Nieda, M | 1 |
| Cartenì, G; Catalano, G; Ciardiello, F; Colucci, G; De Vita, F; Di Martino, N; Galizia, G; Gebbia, V; Giuliani, F; Maiello, E; Manzione, L; Montemurro, F; Orditura, M; Romito, S | 1 |
| Cooney, KA; Dunn, RL; Fardig, JE; Mackler, NJ; Olson, KB; Pienta, KJ; Redman, BG; Smith, DC | 1 |
| Chen, XM; Feng, JX; Wang, YJ; Zhang, X; Zhu, FS | 1 |
| Chiba, N; Gamoh, M; Ishioka, C; Kakudo, Y; Kato, S; Murakawa, Y; Nishino, Y; Ohori, H; Ohtsuka, K; Sakayori, M; Shibata, H; Shimodaira, H; Suzuki, T; Takahashi, M; Takahashi, S; Yamaura, G; Yasuda, K; Yoshioka, T | 1 |
| Slovin, SF | 1 |
| Bilgi, O; Doğan, B; Kandemir, EG; Karagoz, B; Kunter, E; Turken, O | 1 |
| Alimirah, F; Chen, J; Choubey, D; Ho, SM; Panchanathan, R; Zhang, X | 1 |
| Balta, Z; Büttner, R; Fischer, HP; Hirner, A; Sauerbruch, T | 1 |
| Castro, MA; Gelain, DP; Grivicich, I; Klamt, F; Moreira, JC; Passos, DT | 1 |
| Albain, KS; Chansky, K; Crowley, JJ; Gandara, DR; Gaspar, LE; Jett, J; Kelly, K; Lau, DH; Ung, YC | 1 |
| Azuma, H; Inamoto, T; Katsuoka, Y; Kiyama, S; Kotake, Y; Nishimura, Y; Sakamoto, T; Segawa, N; Takahara, K; Ubai, T | 1 |
| Alberto, P; Barrelet, L; Cavalli, F; Goldhirsch, A; Holdener, EE; Joss, RA; Mermillod, B; Obrecht, JP; Siegenthaler, P | 1 |
| De Vries, EG; Meinesz, AF; Mulder, NH; Orie, JL; Postmus, PE; Sleijfer, DT; Van der Geest, S; Vriesendorp, R | 1 |
| Lamanna, S; Lopes-Pegna, A; Marino, C; Mazzei, T; Nozzoli, F; Periti, P; Righi, R; Santomaggio, C | 1 |
| Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, RA; Sonntag, RW | 1 |
| Bitran, JD; Golomb, HM; Hoffman, PC | 1 |
| Hansen, HH; Pedersen, AG | 1 |
| Blum, RH; Foreman, JD; Muggia, FM | 1 |
| Berdel, WE; Diehl, V; Graubner, M; Gropp, C; Klippstein, T; Mende, S; Mitrou, PS | 1 |
| Gatzemeier, U; Hossfeld, DK; Radenbach, D; Zschaber, R | 1 |
| Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, RA; Mermillod, B | 1 |
| Fujita, K; Murayama, T; Sayama, T | 1 |
| Blessing, JA; Homesley, HD; Slayton, RE | 1 |
| Berdel, WE; Diehl, V; Graubner, M; Gropp, C; Klippstein, TH; Mende, S; Mitrou, PS | 1 |
| Booser, DJ; Carr, DT; Chiuten, DF; Dhingra, HM; Farha, P; Issell, BF; Murphy, WK; Spitzer, G; Umsawasdi, T; Valdivieso, M | 1 |
| Bitran, JD; Ward, K | 1 |
| Alberts, DS; Dorr, RT | 1 |
| Aisner, J; Fuks, JZ; Levitt, M; Ostrow, S; Schipper, H; Van Echo, DA; Wiernik, PH | 1 |
| Brattain, MG; Long, BH; Musial, ST | 3 |
| Cheng, E; Dukeman, M; Heelan, R; Kelsen, DP; Magill, GB; Sordillo, P; Yagoda, A | 1 |
| Chapman, JD; Elliott, FG; Lakey, WH; Mador, D; McPhee, MS; Meeker, B; Moore, R; Ritchie, B | 1 |
| Eagan, RT | 1 |
| Klastersky, J; Longeval, E | 1 |
| Arsenau, JC; Blessing, J; Lewis, GC; Slavik, M | 1 |
| Demitrish, M; Duffin, H; Enochs, K; Groshko, G; Lockhard, C; Maniscalco-Greb, E; Vaughn, CB | 1 |
| Casper, ES; Chapman, RA; Golbey, RB; Gralla, RJ; Itri, LM; Kelsen, DP | 1 |
| Brunner, KW; Cavalli, F; Goldhirsch, A; Joss, R; Kaplan, S; Obrecht, JP; Sonntag, R; Weber, W | 1 |
| Demachi, H; Konishi, K; Kuroda, Y; Tsugawa, K; Tsuji, M; Yabushita, K | 1 |
| Muraki, J; Nakazono, M | 1 |
| Ahn, C; Akman, SA; Doroshow, JH; Forman, SJ; Leong, LA; Margolin, KA; Morgan, RJ; Nagasawa, S; Raschko, JW; Somlo, G | 1 |
| Charrot-Chinet, P; Chauvergne, J; Héron, JF; Mayer, F; Toulouse, C | 1 |
| Appel, C; Cummings, G; Esper, PS; Flaherty, LE; Hussain, M; Pienta, KJ; Redman, B | 1 |
| Hayakawa, O; Kudo, R; Takehara, M | 1 |
| Hop, WC; Planting, AS; Stoter, G; van der Gaast, A; Verweij, J | 1 |
| Campbell, K; Huberman, M; Posner, M; Stuart, K | 1 |
| Benson, AB; Clark, JL; Douglass, HO; Haller, DG; Küçük, O; Mansour, EG; Neuberg, DS; Pandya, KJ; Taylor, SG | 1 |
| Klinke, F; Micke, O; Rübe, C; von Eiff, M; Wagner, W; Willich, N | 1 |
| Beltrán, M; Canals, E; Dorca, J; Fuentes, R; Izquierdo, A; Viladiu, P | 1 |
| Cornbleet, MA; Crellin, RP; McIntyre, MA | 1 |
| Adenis, A | 1 |
| Igawa, M; Kadena, H; Nakamoto, T; Tacho, T; Usui, T | 1 |
| Crowell, EB; Higa, GM; Wise, TC | 1 |
| Dive, C; Hickman, JA; Morris, ID; Wakeling, AE; Wilson, JW | 1 |
| Hara, K; Iwasaka, T; Matsuo, N; Mvula, M; Nakao, Y; Sugimori, H; Yamasaki, F; Yokoyama, M | 1 |
| Bosl, GJ; Chaganti, RS; Mazumdar, M; Motzer, RJ; Reuter, VE; Rodriguez, E | 1 |
| Andoh, S; Fujisawa, Y; Hasegawa, Y; Itoh, K; Kotoh, S; Kumazawa, J; Naito, S; Omoto, T; Sagiyama, K; Ueda, T | 1 |
| Fujita, H; Ishizaki, T; Itoh, R; Okada, H; Yamamoto, T; Yasuda, J | 1 |
| Horiuchi, Y; Ina, K; Iwase, H; Kaneko, H; Kuroiwa, A; Kusugami, K; Morise, K; Oka, Y; Shinoda, M; Suga, S | 1 |
| Ahn, C; Akman, SA; Doroshow, JH; Forman, SJ; Leong, LA; Margolin, KA; Morgan, RJ; Raschko, JW; Sniecinski, I; Somlo, G | 1 |
| Chang, KJ; Chen, BR; Chen, YC; Cheng, AL; Lee, PH; Lee, WJ; Lin, JT; Wang, CH; Wang, TH; Yeh, KH | 1 |
| Hondoh, T; Kimura, T; Mitsuya, T; Miyakawa, Z; Moriyama, S; Notake, Y; Shimizu, A; Watanabe, S; Yoshida, K | 1 |
| Chin, K; Hattori, T; Hayakawa, M; Maeda, H; Morise, K; Morooka, Y; Saito, H; Sugihara, M | 1 |
| Horichi, H; Kumaki, T; Matsuki, N; Shima, K; Tajima, H; Takeda, T | 1 |
| Kurimoto, H; Okamura, T; Ono, K; Sakata, Y; Uenishi, M | 1 |
| Cummings, GD; Flaherty, LE; Hussain, MH; Pienta, KJ; Redman, BG | 1 |
| Hagiwara, Y; Kanayama, T; Kobayashi, H; Koezuka, M; Miyawaki, Y; Nakagawa, H; Tokiyoshi, K; Tsuruzono, K; Yamada, M | 1 |
| Borsellino, N; Cipolla, C; Florena, M; Gebbia, V; Latteri, M; Leo, P; Longo, A; Sciume, C; Testa, A; Valenza, R | 1 |
| Lorico, A; Rappa, G; Sartorelli, AC | 2 |
| Ajani, J; David, C; DuBrow, R; Fornage, B; Levin, B; Lynch, P; Roth, J; Roubein, LD | 1 |
| Asbury, RF; Cnaan, A; Haller, DG; Harris, J; Johnson, L; Zaentz, SD | 1 |
| Cascinu, S; Catalano, G; Fedeli, A | 1 |
| Achterrath, W; Berger, M; Berns, T; Fink, U; Harstrick, A; Knipp, H; Meyer, HJ; Preusser, P; Stahl, M; Wilke, H | 1 |
| Acimovic, LJ; Jeremic, B; Matovic, M | 1 |
| Ajani, JA; Dumas, P; Evans, D; Gray, C; Mayer, RJ; Ota, DM; Roh, M; Steele, GD; Sugarbaker, DJ; Vena, DA | 1 |
| Fukunaga, M; Fukunaga, T; Iba, T; Kidokoro, A; Mishima, S; Yagi, Y | 1 |
| Bando, H; Shinohara, T; Sumitani, H; Takishita, Y; Tanaka, H; Yanagawa, H | 1 |
| Donahue, JP; Dulmadge, EA; Vasanthakumar, G; Wilkoff, LJ | 1 |
| Henzen-Logmans, SC; Planting, AS; Stoter, G; van der Gaast, A; Verweij, J | 1 |
| Ihara, H; Kageyama, S; Kawabe, K; Kurita, Y; Mugiya, S; Nakano, M; Suzuki, K; Ueda, D; Ushiyama, T; Yamaguchi, Y | 1 |
| Hirabayashi, M; Kuno, K; Nakagawa, M; Tanaka, Y; Yoshida, H | 1 |
| de Campos, ES; Harris, M; Menasce, LP; Radford, J; Thatcher, N | 1 |
| Adelstein, DJ; Boyce, GA; Bukowski, RM; Kirby, TJ; Rice, TW; Sivak, MV; Van Kirk, MA; van Stolk, RU | 1 |
| Chikamori, M; Genba, K; Ikubo, S; Kimura, I; Kiura, K; Matsumura, T; Matsuo, K; Ohnoshi, T; Tabata, M; Ueoka, H | 1 |
| Adkins, RB; Hoff, SJ; Johnson, DH; Merrill, WH; Murray, MJ; Sawyers, JL; Stewart, JR | 1 |
| Blessing, JA; Major, F; Manetta, A; Markman, M | 1 |
| Azzarello, G; Bari, M; Pappagallo, GL; Rosetti, F; Sampognaro, E; Segati, R; Vinante, O | 1 |
| Gemba, K; Kiura, K; Matsumura, T; Moritaka, T; Ohnoshi, T; Segawa, Y; Shibayama, T; Tabata, M; Takigawa, N; Ueoka, H | 1 |
| Ekman, A; Halme, M; Hand, A; Husgafvel-Pursiainen, K; Linnainmaa, K; Mattson, K; Mattson, M; Pelin, K; Vallas, M | 1 |
| Mori, K; Suga, Y; Takahashi, T; Tominaga, K | 1 |
| Ajani, JA; Gutterman, JU; Levin, B; McMurtrey, M; Pazdur, R; Putnam, JB; Roth, JA; Ryan, MB | 1 |
| Fujita, J; Kubo, A; Takahara, J; Takigawa, K; Yamagishi, Y; Yamaji, Y | 1 |
| Akagi, S; Kawakami, T; Koide, I; Masuda, Y; Ogawa, A; Ogawara, T; Takiguchi, S; Tamura, S; Watanabe, S | 1 |
| Ciavattini, A; Cignitti, M; De Nictolis, M; Garzetti, GG; Goteri, G; Romanini, C; Tranquilli, AL | 1 |
| Lehr, JE; Pienta, KJ | 1 |
| Bajetta, E; Di Bartolomeo, M; Di Leo, A; Zampino, MG | 1 |
| Auerbach, M; Essig, L; Fryer, D; Fryer, J; Lokich, J | 1 |
| Ives, RK | 1 |
| Fukuda, H; Hosokawa, K; Kondo, H; Ohtsu, A; Saito, D; Shimada, Y; Shirao, K; Yamao, T; Yoshida, S | 1 |
| Beuzeboc, P; Dieras, V; Dorval, T; Garcia-Giralt, E; Jouve, M; Palangie, T; Paraiso, D; Pierga, JY; Pouillart, P; Scholl, SM | 1 |
| Fang, Y; Song, M; Wang, G; Xu, H | 1 |
| Hidaka, K; Hirohashi, Y; Hisatsugu, T; Kohno, K; Kuwano, M; Sato, S | 1 |
| Breuer, N; Eigler, FW; Fett, W; Fink, U; Makoski, HB; Molls, M; Niebel, W; Sack, H; Schmidt, U; Seeber, S; Siewert, JR; Stahl, M; Stuschke, M; Walz, MK; Wilke, H | 1 |
| Chen, PM; Chiou, TJ; Fan, S; Hsieh, RK; Kung, SP; Tzeng, CH; Wei, CH | 1 |
| Guichard, M; Lartigau, E | 1 |
| Effenbein, GJ; Fields, KK; Perkins, JB | 1 |
| Fujiwara, T; Gochi, A; Hamada, M; Hizuta, A; Orita, K; Takahashi, K; Takakura, N; Tanaka, N | 1 |
| Hanada, T; Isobe, H; Kawakami, Y; Ogura, S; Sukoh, N; Yamazaki, K | 1 |
| Shen, H; Xiong, W | 1 |
| Conrad, CA; Hong, WK; Verschraegen, C | 1 |
| Anderson, N; Bern, M; Coco, F; Dow, E; Lokich, J; Moore, C | 1 |
| Flaherty, L; Katato, K; Varterasian, M | 1 |
| Hayasaka, S; Kinuwaki, E; Komatsu, H; Nakabayashi, T; Nakai, Y; Niitani, H; Nishikawa, H; Ohizumi, K; Saito, R; Shimizu, T | 1 |
| Bolzicco, G; Crinó, L; De Marinis, F; Emiliani, E; Figoli, F; Gentile, A; Marangolo, M; Maranzano, E; Masiero, P; Meacci, L; Morandi, MG; Ricardi, U; Rosti, G; Scagliotti, GV; Tonato, M | 1 |
| Hejna, M; Kornek, GV; Raderer, M; Rosen, H; Scheithauer, W; Schiessel, R; Schoder, M; Schratter-Sehn, AU; Zach, M | 1 |
| Conroy, T; Curran, D; de Graeff, A; Hoogenraad, WJ; Lusinchi, A; Rougier, P; Sahmoud, T; Taal, BG; Veenhof, CH; Wagener, DJ; Wils, J | 1 |
| Hayashi, N; Ikeba, K; Kinoshita, K; Ohokubo, T; Sodemoto, T; Takagi, A; Takeda, S; Yamamoto, T | 1 |
| Fujii, K; Fukuda, T; Hoshino, T; Ishii, T; Komatsu, M; Masamune, O; Mikami, K; Ohshima, S; Ono, T | 1 |
| Blessing, JA; Creasman, WT; Lewandowski, GS; Rose, PG; Webster, KD | 1 |
| Cho, CC; Gray, DJ; Jones, JJ; Laufman, LR; Spiridonidis, CH; Young, DC | 1 |
| Asano, K; Iizuka, N; Ohishi, Y; Onodera, S; Takeuchi, H; Tashiro, K; Wada, T; Yanada, S | 1 |
| Belli, M; Bianco, A; Cioffi, R; Comella, G; Comella, P; Curcio, C; De Cataldis, G; Della Vittoria, M; Frasci, G; Ianniello, G; Maiorino, L; Panza, N; Perchard, J | 1 |
| Belón, J; Blanco, E; Espinosa, E; Feliu, J; Garcia Alfonso, P; Garcia Girón, C; Garrido, P; González Barón, M; Jara, C; Ruiz, A; Vincent, JM; Zamora, P | 1 |
| Boerrigter, L; Mooi, WJ; Rodenhuis, S; Slebos, RJ; Top, B; van Zandwijk, N; van't Veer, L | 1 |
| Abe, S; Fujita, A; Hayashi, I; Kawakami, Y; Kurita, Y; Matsuda, T; Nakabayashi, T; Nishiwaki, Y; Noda, K; Oshita, F; Saijo, N; Suzuki, S; Takahashi, S; Tamura, T; Tobise, K; Tsuchiya, S | 1 |
| Betsuyaku, T; Hanada, T; Hasegawa, A; Hizawa, N; Isobe, H; Kawakami, Y; Ogura, S; Yamazaki, K | 1 |
| Ekström, K; Enander, LK; Glimelius, B; Graf, W; Haglund, U; Heuman, R; Hoffman, K; Linné, T; Sellström, H; Sjödén, PO; Svensson, C | 1 |
| Boardman, P; Braybrooke, JP; Ganesan, TS; Harris, AL; O'Byrne, KJ; Propper, DJ; Salisbury, AJ; Saunders, MP; Talbot, DC; Taylor, M | 1 |
| Akbulut, H; Cay, F; Demirkazik, A; Dinçol, D; Içli, F; Karaoguz, H | 1 |
| Zukowska, H; Zwoliński, J | 1 |
| Fujimura, S; Kobayashi, S; Okada, S; Yoshida, H | 1 |
| Beuzeboc, P; Diéras, V; Dorval, T; Garcia-Giralt, E; Jouve, M; Palangié, T; Pierga, JY; Pouillart, P; Scholl, SM | 1 |
| Hou, Y; Liu, QY; Ribecco, M; Sikorska, M; Walker, PR | 1 |
| Irwin, JF; Poussin-Rosillo, H; Sardi, A; Waterfield, W | 1 |
| Radzikowska, E; Rowińska-Zakrzewska, E; Sakowicz, A; Załeska, J; Zych, J | 1 |
| Camoriano, JK; Fitch, TR; Frytak, S; Rajkumar, SV; Rubin, J | 1 |
| Pienta, KJ; Smith, DC | 1 |
| Hamano, K; Maruoka, M; Nagayama, T; Nishikawa, Y | 1 |
| Alivizatos, G; Aravantinos, G; Bamia, C; Constantinidis, C; Deliveliotis, C; Dimopoulos, C; Dimopoulos, MA; Kastriotis, I; Kostakopoulos, A; Panopoulos, C; Pantazopoulos, D; Zervas, A | 1 |
| Aoyagi, K; Aoyagi, Y; Asao, T; Okazaki, S; Sano, M; Utsugi, T; Wierzba, K; Yamada, Y | 1 |
| Blessing, JA; Homesley, HD; Mayer, AR; Rose, PG | 1 |
| Benderra, Z; Manfait, M; Morjani, H; Trussardi, A | 1 |
| Aebi, S; Fink, D; Haas, M; Howell, SB; Kim, HK; Nebel, S; Norris, PS | 1 |
| Cesano, A; Miller, EJ; Santoli, D; Torosian, MH; Visonneau, S | 1 |
| Kamiyama, H; Kawashima, K; Koike, N; Morishita, Y; Ogawa, T; Ohwada, S; Sato, Y; Takeyoshi, I | 1 |
| Chang, J; Chow, W; Correia, J; Dancey, J; Dulude, H; Franssen, E; Gallant, G; Girouard, M; Goel, R; Verma, S; Warner, E | 1 |
| Obłakowski, P; Radzikowska, E; Rowińska-Zakrzewska, E; Słodkowska, J; Załeska, J; Zych, J | 1 |
| Bobichon, H; Delvincourt, C; Faroux, MJ; Gorisse, MC; Jardillier, JC; Poitevin, G; Trussardi, A | 1 |
| Müller, C; Stahl, M; Stuschke, M; Vanhoefer, U; Walz, MK; Wilke, H | 1 |
| Fukuda, K; Hara, K; Iwasaka, T; Nakao, Y; Sugimori, H; Uchiyama, M; Yokoyama, M | 1 |
| Aebi, S; Fink, D; Fink, JL; Gordon, R; Howell, SB; Kim, HK; Zheng, H | 1 |
| Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L | 1 |
| Bjarnason, GA; Cripps, C; Dulude, H; Fine, S; Franssen, E; Germond, CJ; Goel, R; Kerr, I; Maroun, JA; Moore, MJ; Oza, AM; Skillings, JR | 1 |
| Hatae, M; Hiura, M; Hoshiai, H; Ikeda, M; Izumi, R; Noda, K; Ogita, Y; Okada, H; Ozaki, M; Ozawa, M; Tamaya, T; Tanaka, K; Yamabe, T | 1 |
| Horie, T; Masutani, M; Sawada, U; Tsujino, I; Yamazaki, T | 1 |
| Blandino, G; Levine, AJ; Oren, M | 1 |
| Craffey, M; Dowlati, A; Levitan, N; MacKay, W; McKenney, J; Remick, SC; Tahsildar, H | 1 |
| Alberto, P; Bacchi, M; Borner, MM; Castiglione, M; Herrmann, R; Honegger, HP; Lange, J; Morant, R; Obrist, R; Roth, AD | 1 |
| Fujita, M; Higashino, K; Tsuchida, T | 1 |
| Bando, E; Fujimura, T; Fujita, H; Fushida, S; Michiwa, Y; Miwa, K; Nishimura, G; Oyama, K; Taniguchi, K; Yonemura, Y | 1 |
| Baly, D; Beryt, M; Coombs, D; Hsu, S; Kabbinavar, F; Lewis, G; Pegram, M; Pietras, R; Slamon, D; Sliwkowski, M | 1 |
| Ajani, J; Dumas, P; Partyka, S | 1 |
| Baek, HJ; Im, YH; Jung, SH; Kang, YK; Kim, BS; Kim, CM; Kim, TY; Kim, YC; Kim, YJ; Park, JH; Ryoo, BY; Shim, YM; Zo, JI | 1 |
| Hirano, K; Honma, T; Mino, K; Nakabayashi, T; Saitoh, H; Takada, M; Takeda, T; Wada, I; Yokouchi, M | 1 |
| Fujiwara, Y; Isobe, T; Katoh, O; Kurata, T; Miyazaki, M; Oguri, T; Ohashi, N; Takahashi, T; Yamakido, M; Yokozaki, M | 1 |
| Fukuda, M; Hayakawa, A; Itoh, N; Kohno, S; Mori, H; Oka, M; Sakamoto, T | 1 |
| Kametani, T; Koshida, H; Masuda, S | 1 |
| Daskalakis, A; Lange, W; Musahl, V; von Lintig, F; Waller, CF | 1 |
| Beijnen, JH; de Wit, R; Lieverst, J; Nannan Panday, VR; Rosing, H; Schellens, JH; Schornagel, JH; Schot, M; ten Bokkel Huinink, WW | 1 |
| Ekimoto, H; Mashiba, H; Matsumoto, S; Okamoto, K | 1 |
| Alberts, DS; Delmore, JE; Fine, BA; Hannigan, EV; Liu, PY; Moore, DF; Poplin, EA; Potkul, RK; Wilczynski, S | 1 |
| Ericson, SG; Fortney, J; Gibson, LF; Landreth, KS; Lynch, JP; Magro, G | 1 |
| Fushiki, H; Hasegawa, K; Izumi, R; Kono, I; Nishida, M; Noda, K; Noguchi, H; Okuda, H; Sugimori, H; Takizawa, K; Tanaka, T; Udagawa, Y; Umesaki, N; Yamamoto, K | 1 |
| Esper, P; Pienta, KJ; Redman, B; Smith, DC; Strawderman, M | 1 |
| Ishihara, S; Kato, Y; Kitagawa, T; Nakajima, T; Ninomiya, Y; Yanagisawa, A | 1 |
| Acito, L; Anastasi, P; Bella, M; Bisagni, G; Borrini, A; Buzzi, P; Carpi, A; Cocconi, G; Di Costanzo, F; Frassoldati, A; Mosconi, A | 1 |
| Andras, E; Byhardt, R; Cox, J; Dar, AR; Johnson, D; Komaki, R; Lawton, C; Lee, JS; Movsas, B; Roach, M; Sause, W; Scott, C; Wasserman, T | 1 |
| Asbury, R; Dutcher, JP; Haller, DG; Novik, Y; Ryan, LM; Schutt, A | 1 |
| Ajisaka, H; Bando, E; Fujimura, T; Fushida, S; Hayashi, T; Minatoya, T; Miwa, K; Nishimura, G; Taniguchi, K; Yonemura, Y | 1 |
| Andras, EJ; Byhardt, RW; Graham, ML; Roach, M; Scott, C; Smith, C; Werner-Wasik, M | 1 |
| Chang, FY; Chao, Y; Chi, KH; Hung, HC; King, KL; Li, CP; Teng, HC; Yen, SH | 1 |
| Greco, FA; Hainsworth, JD | 1 |
| Arimoto, J; Bessho, T; Furukawa, T; Hirai, I; Maebeya, S; Matsuyama, K; Naito, Y; Oura, S; Sakurai, T; Suzuma, T; Tanino, H; Yano, T; Yoshimasu, T | 1 |
| Baron, B; Bleiberg, H; Bodenstein, H; Couvreur, ML; Ducreux, MP; Lacave, AJ; Nordlinger, B; Paillot, B; Piedbois, P; Planker, M; Rougier, P; Santos, JG; Schmoll, HJ; Van Cutsem, E; Vanhoefer, U; Wilke, H; Wils, JA | 1 |
| Amoroso, D; Ballestrero, A; Boccardo, F; Ferrando, F; Garuti, A; Gonella, R; Patrone, F; Sessarego, M; Stura, P | 1 |
| Hashine, K; Karashima, T; Nakatsuzi, H; Sumiyoshi, Y; Yamashita, Y | 1 |
| Fowler, JM; Greer, BE; Horowitz, IR; McGuire, WP; Rodriguez, M; Rose, PG; Waggoner, S | 1 |
| Miyama, M; Ogita, S; Tanaka, T; Umesaki, N | 1 |
| Chapman, RA; Gandara, DR; Jacobson, JL; Macdonald, JS; Modiano, M; Moore, DF; Schroder, LE | 1 |
| Arai, T; Hayakawa, K; Kashiki, Y; Shibayama, M; Shibuya, C; Takaya, T; Toshima, S; Yasuda, Y; Yoshimi, N | 1 |
| Belka, C; Berg, C; Engels, IH; Gregor, M; Jänicke, RU; Lauber, K; Porter, AG; Schulze-Osthoff, K; Schwenzer, R; Stepczynska, A; Stroh, C; Wajant, H; Wesselborg, S | 1 |
| Ahmed, K; Davis, AT; Green, JE; Guo, C; Wang, H; Yu, S | 1 |
| Koshiishi, H; Takahashi, E; Tamamoto, F; Utsumi, K | 1 |
| Catalano, G; De Cataldis, G; De Vita, F; Galizia, G; Infusino, S; Lieto, E; Orditura, M; Romano, C | 1 |
| Cornillet-Lefebvre, P; Doco-Fenzy, M; Gruson, N; Jardillier, JC; Masson, L; Potron, G; Proult, M; Struski, S; Trussardi, A; Ulrich, E | 1 |
| Angelelli, B; Bovicelli, A; Ceccarelli, C; Costa, S; Erzén, M; Lipponen, P; Martoni, A; Santini, D; Syrjänen, K; Syrjänen, S; Terzano, P | 1 |
| Kobayashi, A; Yamaguchi, M | 1 |
| Fujishiro, M; Fukuda, H; Fukuda, M; Kunitoh, H; Nishiwaki, Y; Ohe, Y; Saijo, N; Sekine, I; Shinkai, T; Tamura, T | 1 |
| Lasset, C; Merrouche, Y; Negrier, S; Peaud, PY; Rebattu, P; Trillet-Lenoir, V; Voog, E | 1 |
| Inoue, K; Kasahara, K; Shuin, T | 1 |
| Eguchi, T; Fujii, M; Imai, S; Kasakura, Y; Kobayashi, M; Kochi, M; Mochizuki, F | 1 |
| Borel, C; Ducreux, M; Fizazi, K; Le Chevalier, T; Ruffié, P; Saghatchian, M; Théodore, C | 1 |
| Mahyar-Roemer, M; Roemer, K | 1 |
| Hudes, GR; Obasaju, C | 1 |
| Huigsloot, M; Mulder, GJ; Tijdens, IB; van de Water, B | 1 |
| Fujita, S; Hasegawa, T; Ikeda, A; Kaneshiro, E; Katakami, N; Nishimura, T; Nishio, C; Okazaki, M; Umeda, B | 1 |
| Funato, T; Kaku, M; Kozawa, K; Sasaki, T | 1 |
| Glicksman, AS; Liu, L; Weitberg, AB; Yashar, J | 1 |
| Cruz-Caudillo, JC; Liu, Z; Mira, JL | 1 |
| Hinterleitner, T; Kerbl, R; Schwinger, W; Smolle Juettner, FM; Urban, C; Zotter, H | 1 |
| Mao, Y; Mehl, IR; Muller, MT | 1 |
| Bernis, C; de La Cámara, R; Osorio, S | 1 |
| Aotake, T; Horiuchi, T; Matsumura, M; Tabo, T; Tanaka, K; Tanigawa, N; Uchinami, M; Yokomachi, J | 1 |
| Brill, S; Halpern, Z; Khaikin, M; Kouniavsky, G; Papa, M; Zippel, D; Zvibel, I | 1 |
| Fusco, N; Greer, B; McGuire, W; Rodriguez, M; Rose, PG; Walker, J | 1 |
| Emile, JF; Germann, N; Goldwasser, F; Gross-Goupil, M; Misset, JL; Reynes, M; Wasserman, E | 1 |
| Beckmann, C; Flury, R; Frei, P; Holdener, E; Jungi, WF; Senn, HJ | 1 |
| Bauer, M; Bennett, JM; Creech, R; Hahn, RG; Wampler, G; Wolter, J | 1 |
| Creagan, ET; Eagan, RT; Fleming, TR; Frytak, S; Ingle, JN; Kvols, LK; Rubin, J | 1 |
| Creagan, ET; Eagan, RT; Frytak, S; Ingle, JN; Kvols, LK; McMachon, RT; Rubin, J | 1 |
| Hahn, RG; Moertel, CG; Perry, MC; Reitemeier, RJ; Schutt, AJ | 1 |
| Brunner, KW; Cavalli, F; Hasler, E; Martin, J; Ryssel, HJ; Sonntag, RW; Tschopp, L | 1 |
| Ahmann, DL; Bisel, HF; Eagan, RT | 1 |
| Beck, H; Capranico, G; Gazdar, AF; Giaccone, G; Zunino, F | 1 |
| Fujita, J; Fujita, T; Irino, S; Kubo, A; Morikawa, N; Shiotani, T; Takahara, J; Takigawa, K; Yamagishi, Y; Yamaji, Y | 1 |
| Alftan, H; Lehtovirta, P; Leminen, A; Stenman, UH | 1 |
| Bando, H; Shinohara, T; Takishita, Y; Tanaka, H; Yanagawa, H | 1 |
| Dhingra, HH; Greenberg, J; Hong, WK; Lee, JS; Shirinian, M | 1 |
| Hirai, M | 2 |
| Greco, FA; Hainsworth, JD; Johnson, DH | 3 |
| Higashihara, T; Hojo, K; Kajiyama, K; Kumasaka, Y; Nishiyama, S; Okada, M; Oku, Y | 1 |
| Chiba, M; Hayashi, K; Inaba, Y; Kudo, K; Otsuka, S; Watabe, S | 1 |
| Ben-Baruch, G; Brenner, H; Menczer, J; Rizel, S | 1 |
| Altermatt, HJ; Donatsch, P; Hiestand, PC; Keller, RP; Laissue, JA; Zihlmann, H | 1 |
| Gonin, R; Lerner, A; Mayer, RJ; Steele, GD | 1 |
| Daniels, M; Estapé, J; Grau, JJ; Palombo, H; Solá, C; Viñolas, N | 1 |
| Adelstein, DJ; Boyce, GA; Kirby, TJ; Rice, TW; Sivak, MV | 1 |
| Fukunaga, M; Fukunaga, T; Iba, T; Kawabata, M; Kidokoro, A; Sugiyama, K; Yagi, Y | 1 |
| Fushiki, H | 1 |
| Hayward, IP; Hurst, T; Khoo, SK; Parsons, PG | 1 |
| Kennedy, A; Khansur, T | 1 |
| Aoki, Y; Hiura, K; Katoh, O; Kuroki, S; Yamada, H | 1 |
| Henzen-Logmans, SC; Rodenburg, CJ; Stoter, G; van der Gaast, A; Verweij, J | 1 |
| Bachy, B; Caillaud, JM; Flamant, F; Gruner, M; Hemet, J; Lefur, R; Lemerle, J; Tron, P; Vannier, JP | 1 |
| Brattain, MG; Casazza, AM; Long, BH; Lorico, A; Wang, L; Wang, RC | 1 |
| Marshall, E; Metcalf, C; Trotter, JM | 1 |
| Bisagni, G; Boni, C; Ceci, G; Cocconi, G; Di Blasio, B; Passalacqua, R | 1 |
| Astone, A; Barone, C; Cassano, A; Fontana, T; Garufi, C; Grieco, A; Noviello, MR; Pacelli, F; Ricevuto, E | 1 |
| Ohtagaki, S; Toge, T; Toi, M; Yagi, M; Yoshinaka, K | 1 |
| Karsai, H; Little, C; Murray, N; Osoba, D; Page, R; Shah, A | 1 |
| Bonomi, P; Gale, M; Kittle, CF; Lee, MS; Phillips, A; Purl, S; Reddy, S; Rowland, K; Taylor, SG; Warren, W | 1 |
| Bitran, JD; Comis, RL; Ettinger, DS; Harris, CL; Harwood, KV; Keller, JH; Langer, CJ; Losada, M | 1 |
| Asamoto, H; Fujii, H; Kawaguchi, H; Kawakami, A; Ozawa, Y; Sawano, T; Tsutsumi, T | 1 |
| Ajani, JA; Ames, FC; Boddie, A; Hohn, D; Jackson, DE; Jessup, JM; Levin, B; McBride, C; Ota, DM; Roh, M | 1 |
| Itoyama, Y; Kitano, I; Kochi, M; Korematsu, K; Kuratsu, J; Seto, H; Uemura, S; Ushio, Y | 1 |
| Abbruzzese, JL; Faintuch, J; Frost, P; Raber, MN; Sumrall, C | 1 |
| Bagshawe, KD; Begent, RH; Ledermann, JA; Newlands, ES; Philip, PA; Rustin, GJ | 1 |
| Bertrand, R; Jenkin, J; Kerrigan, D; Pommier, Y; Sarang, M | 1 |
| Kido, Y; Mori, T; Ogawa, M; Ohashi, I; Sakurai, M; Shiozaki, H; Tahara, H | 1 |
| Comis, RL; Hogan, M; LaCreta, F; O'Dwyer, JL; O'Dwyer, PJ; Rosenblum, N | 1 |
| Ekimoto, H; Ishii, T; Kusama, K; Okamoto, K; Takahashi, K | 1 |
| Baker, TR; Fanning, J; Piver, MS | 1 |
| Larsson, R; Nygren, P | 1 |
| Bacchi, M; Bartolucci, R; Bisagni, G; Boni, C; Ceci, G; Cocconi, G; Colozza, MA; De Lisi, V; Lottici, R; Mosconi, AM | 1 |
| Bureau, G; Cordier, R; Dabouis, G; Klastersky, J; Lecomte, J; Libert, P; Ravez, P; Sculier, JP; Thiriaux, J; Vandermoten, G | 2 |
| Achterrath, W; Gatzemeier, U; Heckmayr, M; Hossfeld, D; Lenaz, L; Neuhauss, R | 1 |
| Asamoto, H; Fujii, H; Kawakami, A; Ozawa, Y; Tsutsumi, T | 1 |
| Brandes, A; Cipriani, A; Favaretto, A; Festi, G; Fornasiero, A; Ghiotto, C; Paccagnella, A; Pappagallo, G; Vinante, O; Volpi, A | 1 |
| Creger, RJ; Fox, RM; Lazarus, HM | 1 |
| Beauduin, M; Bosly, A; Duprez, P; Humblet, Y; Majois, F; Prignot, J; Schallier, D; Symann, M; Weynants, P | 1 |
| Pizzillo, MF; Salva, KM; Schwartz, EL; Sparano, JA; Wadler, S; Wiernik, PH | 1 |
| Browne, MJ; Calabresi, P; Clark, JW; Cummings, FJ; Curt, G; Posner, M; Slapak, CA; Urba, S; Weitberg, A; Wiemann, M | 1 |
| Kondoh, I; Moriyama, M; Murai, T | 1 |
| Alberts, DS; Asbury, RF; Boros, L; Goodman, TL; Hickox, DE; Peng, YM; Penn, TE | 1 |
| Elliott, TE; Gerstner, JB; Hahn, RG; Mailliard, JA; Moertel, CG; Tschetter, LK; Wieand, HS | 1 |
| Chung, HC; Kim, BS; Lee, JT; Lee, KB; Lee, SI; Min, JS; Park, YJ; Roh, JK | 1 |
| Abbruzzese, JL; Ajani, JA; DeCaro, L; Jackson, DE; Levin, B; McMurtrey, M; Mountain, C; Rich, TA; Roth, JA; Ryan, B | 1 |
| Kinoshita, K; Kojima, T; Sakamoto, S; Takada, S; Takeda, S | 1 |
| Evans, WK; Osoba, D; Rusthoven, JJ; Shepherd, FA; Turnbull, KA | 1 |
| Ito, M | 1 |
| Akatsuka, Y; Ando, T; Hayakawa, M; Kokubu, K; Kuwahara, Y; Morise, K; Sakai, T; Sato, Y; Tahara, H; Thin, K | 1 |
| Fujimori, Y; Hata, T; Hirano, M; Ikeda, S; Okada, T; Tajima, H; Tomioka, Y; Yoshida, T | 1 |
| Beitz, J; Cummings, F; Posner, MR; Weitberg, AB; Zelkowitz, RS | 1 |
| Andoh, T; Hayashi, H; Kiyama, T; Miyamoto, M; Mizutani, T; Nishi, K; Nomura, T; Onda, M; Tokunaga, A; Umehara, M | 1 |
| Christiansen, NP; Kennedy, BJ | 1 |
| Burton, GV; Cox, EB; Olsen, GA; Vugrin, D | 1 |
| Eiermann, W; Fateh-Moghadam, A; Hepp, H; Meier, W; Stieber, P | 1 |
| Maruoka, M; Miyauchi, T; Nagayama, T | 1 |
| Daugherty, JP; Fanning, J; Weese, JL | 1 |
| Ashe, SA; Hellström, I; Hellström, KE; Hirschberg, DL; Schreiber, GJ; Senter, PD | 1 |
| Ardizzoni, A; Baracco, F; Capaccio, A; Fabiano, F; Felletti, R; Fusco, V; Gulisano, M; Nosenzo, M; Pastorino, G; Pronzato, P | 1 |
| Bonomi, P; Faber, LP; Hendrickson, FR; Kittle, CF; Lee, MS; Pincus, M; Reddy, S; Rowland, K; Taylor, S; Warren, W | 1 |
| Creagan, ET; Kovach, JS; Richardson, RL | 1 |
| Hayakawa, M; Hayashi, N; Kaneshiro, K; Morise, K; Oka, Y; Suga, S; Suzuki, T; Tsunekawa, H; Umemura, K; Yoshida, H | 1 |
| Becker, H; Bülzebruck, H; Djawid, N; Drings, P; Ruchalla, E; Stiefel, P; Tessen, HW | 1 |
| Bénard, J; Da Silva, J; Riou, G; Teyssier, JR | 1 |
| Carr, DT; Chiuten, DF; Dhingra, HM; Farha, P; Murphy, WK; Spitzer, G; Umsawasdi, T; Valdivieso, M | 1 |
| Drings, P; Manke, HG | 1 |
| Chikata, E; Hara, K; Ito, F; Kado, M; Kanda, T; Matsui, Y; Nakayama, M; Ohshima, S; Sakai, S; Shimokata, K | 1 |
| Kimura, K; Niitani, H | 1 |
| Hara, K; Kado, M; Kanda, T; Matsui, Y; Oshima, S; Shima, K; Shimokata, K; Takenaka, S | 1 |
| Kinameri, K; Kurita, Y; Matsuura, N; Sano, K; Yokoyama, A | 1 |
| Fukuda, Y; Homma, T; Nakata, M; Noguchi, Y; Yoneda, S; Yoshida, S | 1 |
| Colozza, MA; Crinò, L; Davis, S; Grignani, F; Lubansky, K; Tonato, M | 1 |
| Abel, U; Bülzebruck, H; Drings, P; Kleckow, M; Manke, HG; Stiefel, P | 1 |
| Fletcher, WS; Green, JB; Green, SJ; Grozea, PN; Metch, B; O'Bryan, R; Oishi, N; Reed, M; Vaughn, CB | 1 |
| Chen, KM; Hamburger, AW; Hoshi, A; Ishihara, J; Lee, YC; Saijo, N; Sakurai, M; Sano, T; Sasaki, Y; Takahashi, H | 1 |
| Hamada, H; Kurooka, K; Mori, N; Nakajima, I; Nakamura, T; Nakamura, Y; Tanaka, A; Yasutomi, M; Yoshinobu, H | 1 |
| Applewhite, A; Cheng, EW; Magill, GB; Sordillo, PP; Sternberg, CN | 1 |
| Blaive, B; Carles, P; Clary, C; Dongay, G; Guerin, JC; Kleisbauer, JP; Orehek, J; Poirier, R; Saretto, S; Vesco, D | 1 |
| Sou, S; Wakisaka, T | 1 |
| Athanassiades, P; Bacoyiannes, H; Kontoyiannes, D | 1 |
| Ettinger, DS; Finkelstein, DM; Ruckdeschel, JC | 1 |
| Ardizzoni, A; Baracco, F; Canobbio, L; De Palma, M; Faravelli, B; Nosenzo, M; Pronzato, P; Rubagotti, A; Serrano, J; Serrano, S | 1 |
| Fujii, H; Iwai, M; Kashiwadani, M; Maekawa, T; Miyoshi, M; Suyama, Y; Urata, Y | 1 |
| Heston, WD; Hollander, P; Niedzwiecki, D; Scher, HI; Smart, T; Sternberg, C; Watson, RC; Yagoda, A | 1 |
| Piver, MS | 1 |
| Buckner, J; Einzig, A; Heelan, R; Kelsen, DP; Magill, G; Vinciguerra, V | 1 |
| Birch, R; Enas, G; Greco, FA; Hainsworth, JD; Hande, KR; Johnson, DH; Porter, LL; Wolff, SN | 1 |
| Aota, Y; Kinjo, T; Mitsuya, H; Murase, T; Shimoji, T | 1 |
| Heijsteeg, M; Splinter, TA; Zondervan, PE | 1 |
| Nishikawa, K; Okamoto, K; Seki, T; Shibasaki, C; Takahashi, K; Uchida, T | 1 |
11 review(s) available for etoposide and Adenocarcinoma
| Article | Year |
|---|---|
[A case of alpha-fetoprotein-producing gastric cancer with hepatic metastasis successfully treated with combination chemotherapy].
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Stomach Neoplasms | 2008 |
Oncocytic adrenocortical carcinoma.
Topics: Adenocarcinoma; Adrenal Cortex Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality Therapy; Doxorubicin; Embolization, Therapeutic; Etoposide; Humans; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mitotane; Nephrectomy; Ribs; Tomography, X-Ray Computed | 2004 |
[Chemotherapy with mitomycin C, etoposide and cisplatin for adenocarcinoma of the uterine cervix].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Humans; Mitomycin; Neoadjuvant Therapy; Prognosis; Uterine Cervical Neoplasms | 2004 |
Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dexamethasone; Drug Resistance, Neoplasm; Estramustine; Etoposide; Gonadotropin-Releasing Hormone; Growth Substances; Humans; Leuprolide; Male; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Orchiectomy; Osteoblasts; Osteoclasts; Paracrine Communication; Peptides, Cyclic; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Receptors, Androgen; Salvage Therapy; Somatostatin; Survival Analysis; Triptorelin Pamoate | 2006 |
Chemotherapy of metastatic non-small cell bronchogenic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Prognosis; Vinblastine; Vindesine | 1983 |
Etoposide (VP-16) in the treatment of lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Podophyllotoxin; Time Factors | 1983 |
Role of chemotherapy in the treatment of lung cancer: evolving strategies for non-small cell histologies.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Mitoguazone; Vinblastine; Vindesine | 1984 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Indazoles; Lung Neoplasms; Male; Mice; Mitoxantrone; Triazines; Vinblastine; Vindesine | 1984 |
Subacute encephalopathic toxicity of cisplatin.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Blindness; Brain Diseases; Cisplatin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Ondansetron | 1995 |
Paclitaxel and docetaxel in prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estramustine; Etoposide; Genes, bcl-2; Humans; Hydrocortisone; Male; Microtubules; Mitosis; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Palliative Care; Prostatic Neoplasms; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome; Tubulin | 2001 |
The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Etoposide; Humans; Neoplasms, Unknown Primary | 1991 |
141 trial(s) available for etoposide and Adenocarcinoma
| Article | Year |
|---|---|
Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy-Induced Febrile Neutropenia; Early Termination of Clinical Trials; Etoposide; Humans; Hydroxamic Acids; Indoles; Lung Neoplasms; Middle Aged; Panobinostat | 2013 |
Do Cell-Cycle Phase-Specific Markers Predict Disease Grade, Stage, and Outcome in Cervical Carcinoma?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Chemoradiotherapy; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Uterine Cervical Neoplasms; Young Adult | 2015 |
Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; beta 2-Microglobulin; Biomarkers; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chemokine CCL2; Cisplatin; Creatinine; Etoposide; Female; Hepatitis A Virus Cellular Receptor 1; Humans; Lipocalin-2; Lipocalins; Lung Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Neoplasm Proteins; Proto-Oncogene Proteins; Receptors, Virus; ROC Curve; Vinblastine; Vinorelbine | 2015 |
A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Carcinoma, Squamous Cell; Cardia; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Esophageal Neoplasms; Esophagectomy; Etoposide; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Radiotherapy, Adjuvant; Stomach Neoplasms; Survival Analysis | 2009 |
[Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Levoleucovorin; Male; Middle Aged; Nausea; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Survival Rate; Thrombocytopenia; Vomiting | 2009 |
Oral chemotherapy in hormone-refractory prostate carcinoma patients unwilling to be admitted to hospital.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Estramustine; Etoposide; Hospitalization; Humans; Male; Middle Aged; Patient Compliance; Prostatic Neoplasms | 2009 |
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplatin; Docetaxel; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids | 2010 |
Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Female; Gastrectomy; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Analysis | 2010 |
Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Dose/dense metronomic chemotherapy with fractioned cisplatin and oral daily etoposide enhances the anti-angiogenic effects of bevacizumab and has strong antitumor activity in advanced non-small-cell-lung cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Angiopoietin-1; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Survival Rate; Thrombospondins; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Phase II clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 101 Group Study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Irinotecan; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Hysterectomy; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Radiotherapy, Adjuvant; Survival Rate; Uterine Cervical Neoplasms | 2011 |
Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Estramustine; Etoposide; Humans; Injections, Intravenous; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Risk Factors | 2011 |
Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Differentiation; Chromogranin A; Disease-Free Survival; Etoposide; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Neuroendocrine Cells; Orchiectomy; Prospective Studies; Prostatic Neoplasms | 2011 |
Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2011 |
Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/refractory epithelial ovarian cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Platelets; Carboplatin; Cisplatin; Combined Modality Therapy; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Granulosa Cell Tumor; Humans; Middle Aged; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Peripheral Nervous System Diseases; Salvage Therapy; Tamoxifen; Thrombocytopenia; Treatment Outcome | 2011 |
Radiotherapy alone versus radiochemotherapy in patients with stage IIIA adenocarcinoma (ADC) of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Radiotherapy; Time Factors | 2013 |
Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Etoposide; Feasibility Studies; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Safety; Salvage Therapy; Survival Rate | 2002 |
Etoposide, doxorubicin and cisplatin alternating with 5-fluorouracil, doxorubicin and high-dose methotrexate in patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2002 |
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Ketoconazole; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2003 |
Prolonged oral etoposide in recurrent or advanced non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Adenosquamous; Drug Administration Schedule; Etoposide; Female; Humans; Middle Aged; Uterine Cervical Neoplasms | 2003 |
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Estramustine; Etoposide; Humans; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Survival Rate; Treatment Outcome | 2003 |
Paclitaxel, carboplatin, and oral etoposide in advanced gastric adenocarcinoma: association with severe myelotoxicity.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Etoposide; Female; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms; Treatment Failure | 2003 |
Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Estramustine; Etoposide; Fatigue; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Sepsis; Survival Analysis; Treatment Outcome | 2003 |
Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leucovorin; Maximum Tolerated Dose; Middle Aged; Tegafur; Uracil | 2003 |
Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Dexamethasone; Diabetes Mellitus; Disease-Free Survival; Estramustine; Etoposide; Gastrointestinal Diseases; Gonadotropin-Releasing Hormone; Hematologic Diseases; Humans; Life Tables; Male; Middle Aged; Orchiectomy; Peptides, Cyclic; Prostatic Neoplasms; Somatostatin; Survival Analysis; Treatment Outcome; Triptorelin Pamoate | 2004 |
A feasibility study in oesophageal carcinoma using deep loco-regional hyperthermia combined with concurrent chemotherapy followed by surgery.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Etoposide; Feasibility Studies; Female; Humans; Hyperthermia, Induced; Male; Middle Aged; Neoplasm Staging; Patient Selection; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Long-term follow-up of a pilot phase II study with neoadjuvant epidoxorubicin, etoposide and cisplatin in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Epirubicin; Etoposide; Female; Follow-Up Studies; Glucuronates; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Stomach Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagogastric Junction; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Levoleucovorin; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Phase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etoposide; Follow-Up Studies; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2005 |
Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Rate; Treatment Outcome | 2005 |
Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome | 2005 |
Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Korea; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2006 |
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Stomach Neoplasms | 2007 |
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Estramustine; Etoposide; Feasibility Studies; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycins | 1984 |
Chemotherapy of metastatic non-small cell bronchogenic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Prognosis; Vinblastine; Vindesine | 1983 |
Role of chemotherapy in the treatment of lung cancer: evolving strategies for non-small cell histologies.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lung Neoplasms; Mitoguazone; Vinblastine; Vindesine | 1984 |
[Cisplatin, vindesine and VP 16-213 in the treatment of inoperable non-small cell bronchial carcinoma. A clinical phase II study].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Vinblastine; Vindesine | 1984 |
New agents in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Alkylating Agents; Animals; Anthraquinones; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Indazoles; Lung Neoplasms; Male; Mice; Mitoxantrone; Triazines; Vinblastine; Vindesine | 1984 |
Randomized study of cyclophosphamide, doxorubicin, and etoposide (VP16-213) with or without cisplatinum in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Random Allocation | 1983 |
High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Diarrhea; Doxorubicin; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Remission Induction; Risk Factors; Sepsis; Stem Cell Transplantation; Stroke Volume; Survival Rate; Transplantation, Autologous | 1994 |
[Chemotherapy of cancers of the uterine cervix with a combination of bleomycin, mitomycin, cisplatin and etoposide].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Middle Aged; Mitomycins; Uterine Cervical Neoplasms | 1993 |
Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Estramustine; Etoposide; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction; Survival Rate | 1994 |
Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Prognosis; Remission Induction | 1995 |
Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Male; Salvage Therapy; Survival Analysis | 1995 |
Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer. An Eastern Cooperative Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Remission Induction; Stomach Neoplasms; Survival Analysis | 1995 |
[Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain; Carboplatin; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Rate; Vindesine | 1995 |
Phase II trial of carboplatin in combination with etoposide in locally advanced large cell carcinoma and adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1995 |
Preliminary results of methotrexate, etoposide and cisplatin in the treatment of urothelial cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Etoposide; Female; Humans; Male; Methotrexate; Middle Aged; Remission Induction; Survival Rate; Urologic Neoplasms | 1995 |
Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Doxorubicin; Drug Resistance; Estrogens; Etoposide; Gonadotropin-Releasing Hormone; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Treatment Outcome | 1995 |
[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Proportional Hazards Models; Stomach Neoplasms; Survival Rate; Tegafur; Uracil; Vomiting | 1995 |
Combination chemotherapy with Tegafur. Uracil (UFT), etoposide, adriamycin and cisplatinum (UFT-EAP) for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukopenia; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Stomach Neoplasms; Survival Analysis; Tegafur; Uracil | 1994 |
Etoposide, doxorubicin (Adriamycin) and cisplatin regimen in advanced gastric adenocarcinoma: experience with a lower dose schedule.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Stomach Neoplasms | 1994 |
An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer.
Topics: Aclarubicin; Adenocarcinoma; Adjuvants, Immunologic; Antineoplastic Agents; Etoposide; Female; Humans; Male; Mitoxantrone; Organometallic Compounds; Pancreatic Neoplasms; Spiro Compounds; Survival Rate | 1994 |
Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouracil; Humans; Interferon alpha-2; Interferon-alpha; Leucovorin; Levoleucovorin; Male; Pilot Projects; Recombinant Proteins; Stomach Neoplasms | 1994 |
5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Esophageal Neoplasms; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Male; Middle Aged; Remission Induction; Thrombocytopenia; Treatment Outcome | 1994 |
Carboplatin and etoposide in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; Humans; Middle Aged; Stomach Neoplasms | 1993 |
Phase II study of oral administration of etoposide for patients with well- and moderately-differentiated adenocarcinomas of unknown primary site.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary | 1993 |
[Results of combination chemotherapy with etoposide, ifosfamide, peplomycin for advanced prostatic cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Male; Middle Aged; Orchiectomy; Peplomycin; Prognosis; Prostatic Neoplasms; Survival Rate | 1993 |
Metastatic carcinoma of uncertain primary site: a retrospective review of 57 patients treated with vincristine, doxorubicin, cyclophosphamide (VAC) or VAC alternating with cisplatin and etoposide (VAC/PE).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide; Dactinomycin; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasms, Unknown Primary; Retrospective Studies; Vincristine | 1994 |
Adenocarcinoma of the esophagus and gastroesophageal junction. Clinical and pathologic assessment of response to induction chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Esophageal Neoplasms; Esophagogastric Junction; Etoposide; Humans; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Remission Induction; Survival Analysis; Treatment Outcome | 1994 |
Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystadenocarcinoma; Endometriosis; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Parenteral; Middle Aged; Ovarian Neoplasms; Reoperation; Salvage Therapy; Treatment Outcome | 1993 |
The combination of mitomycin, vinblastine and cisplatin is active in the palliation of stage IIIB-IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycins; Neoplasm Staging; Quality of Life; Remission Induction; Vinblastine | 1993 |
Etoposide plus cisplatin followed by thoracic radiation for stage IIIB non-small cell lung cancer: MAOP study 2188.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 1995 |
An early phase II study of etoposide (VP-16) in advanced gastric cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Alopecia; Anemia; Antineoplastic Agents, Phytogenic; Carcinoma, Signet Ring Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Stomach Neoplasms | 1996 |
Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Confidence Intervals; Endometrial Neoplasms; Etoposide; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate | 1996 |
Prospective trial of combined hyperfractionated radiotherapy and bronchial arterial infusion of chemotherapy for locally advanced nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Mitomycins; Neoplasm Staging; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis | 1996 |
Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cause of Death; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Male; Preoperative Care; Survival Analysis; Treatment Failure | 1996 |
Treatment of advanced gastric cancer with a modified regimen of etoposide/leucovorin/5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Stomach Neoplasms | 1996 |
Analysis of dose-response relationships in the setting of high-dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carboplatin; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Retrospective Studies; Survival Rate; Transplantation, Autologous | 1996 |
Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Etoposide; Female; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia | 1996 |
[Early phase II study of oral administration of etoposide for 21 consecutive days in patients with non-small-cell lung cancer].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male | 1995 |
Phase II study of intensive chemotherapy with carboplatin, ifosfamide and etoposide plus recombinant human granulocyte colony-stimulating factor and sequential radiotherapy in locally advanced, unresectable non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Recombinant Proteins; Survival Rate | 1996 |
Effective radiochemotherapy with cisplatin and etoposide for the management of patients with locally inoperable and metastatic esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis | 1996 |
Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy; Survival Rate | 1996 |
[Clinical effect of intra-arterial carboplatin-combined chemotherapy for advanced uterine cervical cancer and increased tissue platinum levels with Lipo PGE1 administration before chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Alprostadil; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carcinoma, Squamous Cell; Cervix Uteri; Chemotherapy, Adjuvant; Epirubicin; Etoposide; Female; Humans; Iliac Artery; Infusions, Intra-Arterial; Infusions, Intravenous; Middle Aged; Mitomycin; Platinum; Uterine Cervical Neoplasms; Vindesine | 1996 |
A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Administration, Oral; Cohort Studies; Endometrial Neoplasms; Etoposide; Female; Humans; Leukopenia; Neoplasm Recurrence, Local; Thrombocytopenia; Time Factors | 1996 |
A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Etoposide; Female; Humans; Male; Middle Aged; Palliative Care; Survival Rate | 1996 |
Cisplatin/carboplatin + etoposide + vinorelbine in advanced non-small-cell lung cancer: a multicentre randomised trial. Gruppo Oncologico Campano.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cause of Death; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Survival Analysis; Vinblastine; Vinorelbine | 1996 |
Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Etoposide; Head and Neck Neoplasms; Humans; Leucovorin; Lung Neoplasms; Middle Aged; Stomach Neoplasms; Tegafur; Uracil | 1997 |
Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged | 1997 |
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Levoleucovorin; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 1997 |
A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Esophageal Neoplasms; Etoposide; Female; Humans; Injections, Intravenous; Male; Middle Aged; Mitomycin; Stomach Neoplasms; Treatment Outcome | 1997 |
Phase II study of a modified combination of etoposide, doxorubicin, and cisplatin for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Leukopenia; Male; Middle Aged; Nausea; Stomach Neoplasms; Survival Analysis; Vomiting | 1997 |
Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Endometrial Neoplasms; Etoposide; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate | 1997 |
Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cause of Death; Cisplatin; Clinical Trials, Phase II as Topic; Cochlea; Digestive System Neoplasms; Drug Administration Schedule; Drug Synergism; Esophageal Neoplasms; Etoposide; Evaluation Studies as Topic; Female; Humans; Kidney; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Remission Induction; Sepsis; Stomach Neoplasms; Thrombocytopenia; Vomiting | 1997 |
Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Alopecia; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; DNA Replication; DNA, Neoplasm; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estramustine; Etoposide; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Microtubules; Nuclear Matrix; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Remission Induction; Tumor Cells, Cultured | 1997 |
Oral estramustine and oral etoposide for hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Male; Middle Aged; Prostatic Neoplasms; Survival Rate | 1997 |
Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds | 1998 |
A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary | 1998 |
[Cytostatic treatment of patients with advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Vinblastine | 1998 |
Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Male; Methotrexate; Middle Aged; Stomach Neoplasms; Survival Analysis | 1998 |
[Late phase II trial of oral etoposide administered for 21 consecutive days in patients with cervical cancer. ETP 21 Study Group--Cervical Cancer Group].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Middle Aged; Nausea; Uterine Cervical Neoplasms; Vomiting | 1998 |
A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appetite Stimulants; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Lung Neoplasms; Male; Megestrol Acetate; Mesna; Middle Aged; Protective Agents; Recombinant Proteins; Survival Analysis; Treatment Outcome | 1998 |
Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Hematologic Diseases; Humans; Male; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 1998 |
Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Etoposide; Female; Fluorouracil; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Leucovorin; Levoleucovorin; Male; Middle Aged; Stomach Neoplasms | 1999 |
Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Esophagogastric Junction; Etoposide; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Proportional Hazards Models; Stomach Neoplasms; Survival Analysis | 1999 |
Induction of gamma-glutamylcysteine synthetase gene expression by platinum drugs in peripheral mononuclear cells of lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Blotting, Northern; Camptothecin; Carboplatin; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression; Glutamate-Cysteine Ligase; Humans; Irinotecan; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Polymerase Chain Reaction; RNA, Messenger; Statistics, Nonparametric; Tumor Cells, Cultured | 1999 |
Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Epirubicin; Erythropoietin; Etoposide; Female; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Methotrexate; Middle Aged; Prospective Studies; Recombinant Proteins; Transplantation Conditioning; Transplantation, Autologous | 1999 |
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasms; Paclitaxel | 1999 |
Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Endometrial Neoplasms; Etoposide; Female; Humans; Middle Aged; Neoplasm Recurrence, Local | 1999 |
Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Etoposide; Female; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Uterine Cervical Neoplasms | 1999 |
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Quality of Life; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome | 1999 |
Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Prospective Studies; Remission Induction; Survival Rate; Treatment Outcome | 1999 |
The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Etoposide; Humans; Karnofsky Performance Status; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prospective Studies; Quality-Adjusted Life Years; Survival Analysis | 1999 |
Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282.
Topics: Aclarubicin; Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Etoposide; Female; Humans; Male; Mitoxantrone; Organometallic Compounds; Spiro Compounds; Stomach Neoplasms | 1999 |
Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disseminated Intravascular Coagulation; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Male; Stomach Neoplasms; Survival Rate | 2000 |
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the Europe
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Levoleucovorin; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Stomach Neoplasms; Survival Analysis | 2000 |
Effects of three cytokine regimens on hematologic recovery and progenitor cell mobilization after high-dose cyclophosphamide, etoposide, and cisplatin.
Topics: Adenocarcinoma; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Cytokines; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cells; Humans; Interleukin-3; Leukocyte Count; Middle Aged; Neutropenia; Thrombocytopenia | 2000 |
Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Male; Middle Aged; Prostatic Neoplasms | 2000 |
Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Leukemia, Myeloid, Acute; Maximum Tolerated Dose; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Thrombocytopenia | 2000 |
A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Interferon alpha-2; Interferon-alpha; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Recombinant Proteins | 2000 |
[Evaluation of bronchial arterial infusion (BAI) for high risk lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Camptothecin; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intra-Arterial; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2000 |
CD44 isoform 6 (CD44v6) is a prognostic indicator of the response to neoadjuvant chemotherapy in cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; alpha Catenin; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Biomarkers, Tumor; Bleomycin; Cadherins; Carcinoma, Adenosquamous; Cisplatin; Cytoskeletal Proteins; Disease-Free Survival; Epirubicin; Etoposide; Female; Glycoproteins; Humans; Hyaluronan Receptors; Hysterectomy; Immunohistochemistry; Middle Aged; Neoadjuvant Therapy; Survival Rate; Trans-Activators; Uterine Cervical Neoplasms | 2001 |
Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged | 2000 |
Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Survival Analysis | 2000 |
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Differentiation; Cisplatin; Etoposide; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Interferon-alpha; Male; Middle Aged; Neoplasms, Unknown Primary; Prospective Studies | 2001 |
A phase I trial of prolonged oral etoposide and liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Schedule; Etoposide; Fallopian Tube Neoplasms; Female; Humans; Liposomes; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms | 2002 |
Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Dianhydrogalactitol; Drug Evaluation; Etoposide; Humans; Kidney Neoplasms; Megestrol; Middle Aged; Neoplasm Metastasis; Podophyllotoxin; Sugar Alcohols | 1979 |
Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; Ethers, Cyclic; Etoposide; Female; Galactitol; Humans; Male; Middle Aged; Podophyllotoxin; Rectal Neoplasms; Sugar Alcohols | 1976 |
Evaluation of VP-16 and the combination of adriamycin and vincristine in advanced breast cancer.
Topics: Adenocarcinoma; Breast Neoplasms; Cell Division; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Neoplasm Metastasis; Podophyllotoxin; Remission, Spontaneous; Vincristine | 1976 |
[Basic and clinical studies of local hyperthermia for prostatic cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Animals; Bleomycin; Cisplatin; Combined Modality Therapy; Dogs; Etoposide; Humans; Hyperthermia, Induced; Male; Middle Aged; Peplomycin; Prostate; Prostatic Neoplasms | 1992 |
Etoposide, doxorubicin, and cisplatin chemotherapy for advanced gastric adenocarcinoma: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Analysis | 1992 |
Phase II trial of carboplatin and etoposide activity in pretreated breast cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Evaluation; Etoposide; Female; Humans; Middle Aged | 1992 |
Association of epirubicin, etoposide and cisplatin in gastric cancer. A phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Etoposide; Humans; Middle Aged; Stomach Neoplasms | 1991 |
Brief intensive chemotherapy for metastatic non-small-cell lung cancer: a phase II study of the weekly CODE regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prednisone; Remission Induction; Survival Rate; Vincristine | 1991 |
Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Fluorouracil; Humans; Middle Aged; Neoplasms, Unknown Primary; Remission Induction; Survival Rate | 1991 |
Pharmacologic study of etoposide and cisplatin by the intraperitoneal route.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Cisplatin; Drug Evaluation; Etoposide; Female; Gastrointestinal Neoplasms; Humans; Infusions, Parenteral; Male; Middle Aged; Ovarian Neoplasms | 1991 |
Phase II trial of cisplatin, adriamycin, and etoposide for metastatic endometrial adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Survival Rate; Uterine Neoplasms | 1991 |
Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Etoposide; Female; Fluorouracil; Humans; Methotrexate; Middle Aged | 1991 |
A randomized trial of two platinum combinations in patients with advanced non-small cell lung cancer: a preliminary report. European Organization for the Research and Treatment of Cancer--Lung Cancer Working Party.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Randomized Controlled Trials as Topic; Survival Rate | 1990 |
Cisplatin, etoposide, and ifosfamide in non-small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Randomized Controlled Trials as Topic; Remission Induction | 1990 |
Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Random Allocation | 1989 |
Combination chemotherapy with etoposide and 5-fluorouracil in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 1989 |
Cisplatin and etoposide: an effective treatment for refractory breast carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Female; Humans; Middle Aged; Neoplasm Metastasis | 1989 |
Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Random Allocation; Vinblastine; Vindesine | 1985 |
VP-16 + adriamycin vs. adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Etoposide; Humans; Middle Aged; Random Allocation; Receptors, Estrogen | 1988 |
Etoposide (VP-16) in the treatment of advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Etoposide; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms | 1988 |
Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Neoplasm Metastasis; Podophyllotoxin; Vincristine | 1986 |
330 other study(ies) available for etoposide and Adenocarcinoma
| Article | Year |
|---|---|
Synthesis and antitumor activity of structural analogues of the epipodophyllotoxins.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Chemical Phenomena; Chemistry; Colonic Neoplasms; Etoposide; Humans; Indans; Leukemia P388; Lung Neoplasms; Mice; Molecular Structure; Podophyllotoxin; Structure-Activity Relationship; Tumor Cells, Cultured | 1991 |
Synthesis and evaluation of new 6-amino-substituted benzo[c]phenanthridine derivatives.
Topics: Adenocarcinoma; Alkaloids; Animals; Antineoplastic Agents; Benzophenanthridines; Breast Neoplasms; Humans; Leukemia L1210; Leukemia P388; Mice; Molecular Structure; Phenanthridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1993 |
Cytotoxic pheophorbide-related compounds from Clerodendrum calamitosum and C. cyrtophyllum.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Cell Survival; Chlorophyll; Dose-Response Relationship, Drug; Drug Resistance; Etoposide; Female; Humans; Ileal Neoplasms; KB Cells; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Spectroscopy; Melanoma; Molecular Structure; Ovarian Neoplasms; Plant Leaves; Plant Stems; Plants, Medicinal; Stereoisomerism; Structure-Activity Relationship; Taiwan; Tumor Cells, Cultured; Vincristine | 2001 |
Cytotoxic oxoisoaporphine alkaloids from Menispermum dauricum.
Topics: Adenocarcinoma; Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cytochrome P-450 Enzyme Inhibitors; Drugs, Chinese Herbal; Enzyme Inhibitors; Female; Humans; Leukemia; Lung Neoplasms; Magnetic Resonance Spectroscopy; Mass Spectrometry; Mice; Molecular Structure; Plant Roots; Plants, Medicinal; Porphyrins; Tumor Cells, Cultured | 2001 |
3-Aryl-2-quinolone derivatives: synthesis and characterization of in vitro and in vivo antitumor effects with emphasis on a new therapeutical target connected with cell migration.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Movement; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Humans; Mammary Neoplasms, Experimental; Mice; Microscopy, Phase-Contrast; Neoplasm Transplantation; Quinolones; Structure-Activity Relationship; Tetrazoles; Tumor Cells, Cultured | 2002 |
Synthesis and structure-activity relationships of novel pyrimido[1,2-b]indazoles as potential anticancer agents against A-549 cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Humans; Indazoles; Lung Neoplasms; Pyrimidines; Quantitative Structure-Activity Relationship; Tubulin | 2007 |
Synthesis and evaluation of mansonone F derivatives as topoisomerase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Survival; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Etoposide; Humans; Inhibitory Concentration 50; Lung Neoplasms; Naphthoquinones; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Plasmids; Pyrans; Quinones; Sesquiterpenes; Structure-Activity Relationship; Telomerase; Topoisomerase Inhibitors | 2011 |
N⁴-Phenyl-substituted 2-acetylpyridine thiosemicarbazones: cytotoxicity against human tumor cells, structure-activity relationship studies and investigation on the mechanism of action.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Death; Cell Line, Tumor; Central Nervous System Neoplasms; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Etoposide; Female; Glioblastoma; Glioma; Humans; Inhibitory Concentration 50; Microtubules; Molecular Structure; Structure-Activity Relationship; Thiosemicarbazones; Tubulin; Tumor Suppressor Protein p53 | 2012 |
Lissoclibadin 1, a Polysulfur Aromatic Alkaloid from the Indonesian Ascidian Lissoclinum cf. badium, Induces Caspase-Dependent Apoptosis in Human Colon Cancer Cells and Suppresses Tumor Growth in Nude Mice.
Topics: Adenocarcinoma; Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Proliferation; Colonic Neoplasms; Female; HeLa Cells; Humans; Indonesia; MCF-7 Cells; Mice; Mice, Nude; Molecular Structure; Urochordata | 2017 |
Combined large cell neuroendocrine carcinoma: clinical characteristics, prognosis and postoperative management.
Topics: Adenocarcinoma; Adult; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Etoposide; Female; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Retrospective Studies | 2022 |
Heterogeneity or transformation? A whack-a-mole case of EGFR-mutant lung adenocarcinoma and small cell carcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Small Cell; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; Mutation; Platinum; Protein Kinase Inhibitors; Small Cell Lung Carcinoma | 2022 |
Sequential small cell transformation and T790M mutation in an epidermal growth factor-mutant lung adenocarcinoma: A rare occurrence with significant management implications.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carboplatin; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Etoposide; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs.
Topics: Adenocarcinoma; Etoposide; Humans; Neuroendocrine Tumors; Pancreatic Neoplasms; Platinum; Retrospective Studies; Somatostatin; Treatment Outcome | 2021 |
TRIM28 knockdown increases sensitivity to etoposide by upregulating E2F1 in non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Etoposide; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Lung Neoplasms; Mice; RNA, Small Interfering; Tripartite Motif-Containing Protein 28; Xenograft Model Antitumor Assays | 2017 |
BCL2 induced by LAMTOR3/MAPK is a druggable target of chemoradioresistance in mesenchymal lung cancer.
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biphenyl Compounds; Cell Proliferation; Cell Survival; Chemoradiotherapy; Diphenylamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Molecular Mimicry; Nitrophenols; Peptide Fragments; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; RNA Interference; Signal Transduction; Sulfonamides; Transfection; Up-Regulation | 2017 |
Inhibitory Effects of Culinary Herbs and Spices on the Growth of HCA-7 Colorectal Cancer Cells and Their COX-2 Expression.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; G1 Phase Cell Cycle Checkpoints; Humans; Plants, Medicinal; Poly(ADP-ribose) Polymerases; Spices; Time Factors | 2017 |
Successful treatment of concomitant metastatic prostate cancer and B-cell non-Hodgkin's lymphoma with R-EPOCH chemotherapy regimen and antiandrogen therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Multiple Primary; Positron-Emission Tomography; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Rituximab; Vincristine | 2018 |
Experience of Treating a Young Patient With Primary Seminal Vesicle Adenocarcinoma.
Topics: Adenocarcinoma; Cisplatin; Combined Modality Therapy; Etoposide; Genital Neoplasms, Male; Humans; Male; Radiotherapy, Adjuvant; Seminal Vesicles; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2018 |
Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell prostate carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Small Cell; Cisplatin; Databases, Factual; DNA Repair; Etoposide; Gene Expression Profiling; Genes, Tumor Suppressor; Genetic Predisposition to Disease; Genomic Instability; Humans; Male; Middle Aged; Neoplasms, Complex and Mixed; Phenotype; Prostatic Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome | 2018 |
Dynamic Changes and Drug-Induced Selection of Resistant Clones in a Patient With EGFR-Mutated Adenocarcinoma That Acquired T790M Mutation and Transformed to Small-Cell Lung Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Transformation, Neoplastic; Clone Cells; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Etoposide; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Small Cell Lung Carcinoma | 2018 |
Outcomes and treatments of IB1 cervical cancers with high recurrence risk: A 13 years' experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Humans; Iridium Radioisotopes; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Recurrence; Retrospective Studies; Risk; Treatment Outcome; Uterine Cervical Neoplasms | 2018 |
Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Nasoethmoidal Intestinal-Type Adenocarcinoma Treated with Cetuximab: Role of Liquid Biopsy and BEAMing in Predicting Response to Anti-Epidermal Growth Factor Receptor Therapy.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cetuximab; Cytarabine; ErbB Receptors; Etoposide; Genotype; Humans; Intestinal Neoplasms; Liquid Biopsy; Male; Melphalan; Paranasal Sinus Neoplasms | 2019 |
Is neoadjuvant chemotherapy followed by radical surgery more effective than radiation therapy for stage IIB cervical cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2013 |
Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aldehyde Dehydrogenase 1 Family; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Calcium-Binding Proteins; CD24 Antigen; Cell Movement; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Etoposide; Female; Fibrosarcoma; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Isoenzymes; Lung Neoplasms; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Retinal Dehydrogenase; RNA Interference; RNA, Small Interfering; Spheroids, Cellular; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2014 |
A whole-body dual-modality radionuclide optical strategy for preclinical imaging of metastasis and heterogeneous treatment response in different microenvironments.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; DNA Damage; Environment; Etoposide; Female; Fluorescence; Humans; Lymph Nodes; Microscopy, Confocal; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Reproducibility of Results; Sodium Pertechnetate Tc 99m; Symporters; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Whole Body Imaging | 2014 |
Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide followed by surgery for thymic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Thymectomy; Thymoma; Thymus Neoplasms; Treatment Outcome; Vincristine | 2014 |
Efficacy and Tolerability of Palliative Split-Course Thoracic Chemoradiotherapy for Symptomatic Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Chest Pain; Cohort Studies; Cough; Dyspnea; Esophagitis; Etoposide; Female; Hemoptysis; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Palliative Care; Pemetrexed; Radiation Injuries; Radiation Pneumonitis; Retrospective Studies; Treatment Outcome | 2015 |
Adjuvant chemotherapy in patients with completely resected small cell lung cancer: a retrospective analysis of 26 consecutive cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Small Cell Lung Carcinoma; Treatment Outcome | 2014 |
Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; Cisplatin; ErbB Receptors; Etoposide; Female; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Retinoblastoma Protein; Sequence Analysis, DNA; Smad4 Protein; Small Cell Lung Carcinoma; Smoking; Tumor Suppressor Protein p53; Young Adult | 2015 |
[Antitumor and antiproliferative action of the steroidal cytostatic antiestrogen cytestrol acetate on hormone-dependent tumor models].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cytostatic Agents; Doxorubicin; Drug Administration Schedule; Drug Synergism; Estrogen Antagonists; Ethinyl Estradiol; Etoposide; Female; Humans; Inhibitory Concentration 50; Injections, Subcutaneous; Mice; Rats; Tamoxifen; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
The Treatment of Pelvic Locoregional Recurrence of Cervical Cancer After Radical Surgery With Intensity-Modulated Radiation Therapy Compared With Conventional Radiotherapy: A Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherapy; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Humans; Hysterectomy; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Prognosis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Remission Induction; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms | 2015 |
Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Remission Induction; Small Cell Lung Carcinoma | 2015 |
Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Adenocarcinoma of Lung; Adenoviridae; Adenovirus E1A Proteins; Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; Chemotherapy, Adjuvant; E2F1 Transcription Factor; Etoposide; Feasibility Studies; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; HEK293 Cells; Homeostasis; Host-Pathogen Interactions; Humans; Lung Neoplasms; MCF-7 Cells; Mice, Inbred NOD; Mice, SCID; Oncolytic Virotherapy; Oncolytic Viruses; Phosphorylation; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Time Factors; Transcription, Genetic; Transfection; Virus Replication; Xenograft Model Antitumor Assays; Y-Box-Binding Protein 1 | 2015 |
Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2016 |
Germ Cell Tumor Targeting Chemotherapy in Gastric Adenocarcinoma with an Endodermal Sinus Tumor Component: A Case Report.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Capecitabine; Cisplatin; Endodermal Sinus Tumor; Etoposide; Humans; Male; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Tomography, X-Ray Computed | 2017 |
Ercc1 Deficiency Promotes Tumorigenesis and Increases Cisplatin Sensitivity in a Tp53 Context-Specific Manner.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Proliferation; Cell Survival; Cisplatin; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Etoposide; Humans; Lung Neoplasms; Mice; Mutation; Precision Medicine; Proto-Oncogene Proteins p21(ras); Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2016 |
[Recurrent Gastric Carcinoma(Endocrine Cell Type)Successfully Treated with Multidisciplinary Therapy - A Case Report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Etoposide; Female; Gastrectomy; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Recurrence; Stomach Neoplasms | 2016 |
ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Etoposide; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Ifosfamide; Male; Middle Aged; Urachus | 2008 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
alpha5-integrin is crucial for L1CAM-mediated chemoresistance in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Caspases; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Humans; Integrin alpha5; Mutagenesis, Site-Directed; Neural Cell Adhesion Molecule L1; Nitric Oxide Synthase Type II; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Transfection; Tumor Cells, Cultured | 2009 |
Survival after trimodality treatment for superior sulcus and central T4 non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Etoposide; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Prognosis; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Tomography, X-Ray Computed | 2009 |
"Burned out" testicular seminoma presenting as a primary gastric malignancy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Diagnosis, Differential; Etoposide; Gastrectomy; Gastroscopy; Humans; Ifosfamide; Immunohistochemistry; Male; Middle Aged; Neoplasms, Unknown Primary; Orchiectomy; Positron-Emission Tomography; Seminoma; Stomach Neoplasms; Testicular Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2009 |
Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Records; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Infusions, Parenteral; Interferon alpha-2; Interferon-alpha; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Retrospective Studies; Survival Analysis; Thiotepa | 2009 |
Enhanced pancreatic cancer gene therapy by combination of adenoviral vector expressing c-erb-B2 (Her-2/neu)-targeted immunotoxin with a replication-competent adenovirus or etoposide.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Etoposide; Gene Targeting; Genetic Therapy; Genetic Vectors; Humans; Immunotoxins; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Pancreatic Neoplasms; Receptor, ErbB-2; Treatment Outcome; Virus Replication | 2010 |
Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Etoposide; Female; Fluorouracil; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Failure | 2010 |
[Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer--report of a case].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Etoposide; Fluorouracil; Gastrectomy; Humans; Immunohistochemistry; Leucovorin; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2009 |
Methylation induced gene silencing of HtrA3 in smoking-related lung cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Large Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Cells, Cultured; Cisplatin; DNA Methylation; Drug Resistance, Neoplasm; Etoposide; Gene Silencing; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Nitrosamines; Serine Endopeptidases; Smoking | 2010 |
Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplatin; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Fluorouracil; Gene Expression Regulation; Glutathione S-Transferase pi; Humans; Immunoblotting; Lactones; Multidrug Resistance-Associated Proteins; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Sulfones | 2010 |
Effects of 17beta-estradiol on the cytotoxicity of etoposide in a lung carcinoma cell line and its bioavailability in ovariectomized Sprague-Dawley rats.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Cell Line, Tumor; Estradiol; Etoposide; Female; Humans; Lung Neoplasms; Ovariectomy; Rats; Rats, Sprague-Dawley | 2010 |
Cisplatin combination chemotherapy induces oxidative stress in advance non small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Etoposide; Female; Follow-Up Studies; Humans; Lipid Peroxidation; Lung Neoplasms; Male; Middle Aged; Nitric Oxide; Oxidative Stress; Superoxide Dismutase; Survival Rate; Treatment Outcome | 2010 |
Suppressed protein expression of the death-associated protein kinase enhances 5-fluorouracil-sensitivity but not etoposide-sensitivity in human endometrial adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Death-Associated Protein Kinases; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Etoposide; Female; Fluorouracil; Gene Knockdown Techniques; Humans; RNA, Small Interfering; Transfection | 2010 |
Complete remission in a patient with metastatic mixed adenocarcinoma/extrapulmonary small cell carcinoma of the prostate.
Topics: Adenocarcinoma; Androgen Antagonists; Bone Neoplasms; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Prostatic Neoplasms; Remission Induction | 2011 |
Expressions of topoisomerase IIα and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Prospective Studies; Real-Time Polymerase Chain Reaction; RNA, Messenger; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vault Ribonucleoprotein Particles; Vincristine | 2011 |
Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Etoposide; Female; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Proto-Oncogene Proteins c-jun; Signal Transduction; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
[Bilateral conjunctival oedema as a symptom of adrenal adenocarcinoma].
Topics: Adenocarcinoma; Adrenal Cortex Neoplasms; Adrenalectomy; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Conjunctival Diseases; Cushing Syndrome; Cyclophosphamide; Diabetes Mellitus, Type 2; Doxorubicin; Edema; Etoposide; Fatal Outcome; Female; Humans; Hydrocortisone; Ketoconazole; Lung Neoplasms; Neoplasm Recurrence, Local; Paraneoplastic Syndromes; Respiratory Insufficiency; Vincristine | 2011 |
Verticillin A overcomes apoptosis resistance in human colon carcinoma through DNA methylation-dependent upregulation of BNIP3.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; DNA Methylation; Drug Resistance, Neoplasm; Etoposide; Fas Ligand Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Indoles; Liver Neoplasms; Membrane Proteins; Mice; Mice, Nude; Neoplasm Proteins; Promoter Regions, Genetic; Proto-Oncogene Proteins; Recombinant Proteins; RNA Interference; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells.
Topics: Adenocarcinoma; Antigens, Neoplasm; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Caspase 3; DNA Damage; DNA Topoisomerases, Type II; DNA-Binding Proteins; Etoposide; Flow Cytometry; Humans; Lung Neoplasms; Piperidines; Podophyllotoxin; Poly(ADP-ribose) Polymerases; RNA, Small Interfering; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2012 |
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Time Factors; Tomography, X-Ray Computed | 2011 |
Proteomic footprinting of drug-treated cancer cells as a measure of cellular vaccine efficacy for the prevention of cancer recurrence.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cancer Vaccines; Chromatography, Liquid; Dendritic Cells; Doxorubicin; Etoposide; Female; Hep G2 Cells; Humans; Neoplasm Recurrence, Local; Proteomics; Receptors, Cell Surface; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; T-Lymphocytes, Cytotoxic; Tamoxifen; Tumor Cells, Cultured | 2012 |
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Down-Regulation; Doxorubicin; Etoposide; Floxuridine; Fluorescent Antibody Technique; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomic Instability; Humans; Irinotecan; Metaphase; Paclitaxel; Polymerase Chain Reaction; Predictive Value of Tests; Protein Array Analysis; Reproducibility of Results; Tegafur; Tissue Array Analysis; Tumor Cells, Cultured; Up-Regulation; Uracil | 2012 |
Quantitative expression analysis of the apoptosis-related genes BCL2, BAX and BCL2L12 in gastric adenocarcinoma cells following treatment with the anticancer drugs cisplatin, etoposide and taxol.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cisplatin; Etoposide; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Muscle Proteins; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms | 2012 |
Octarepeat peptides of prion are essential for multidrug resistance in gastric cancer cells.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Cisplatin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluorouracil; Glutathione; Glutathione Peroxidase; Glutathione Transferase; Humans; Inhibitory Concentration 50; Prions; PrPC Proteins; RNA, Small Interfering; Stomach Neoplasms; Superoxide Dismutase; Transfection; Tumor Cells, Cultured | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cross-Sectional Studies; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2012 |
Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hemorrhage; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Pulmonary Embolism; Retrospective Studies; Risk Factors; Survival Rate | 2012 |
Vincristine enhances amoeboid-like motility via GEF-H1/RhoA/ROCK/Myosin light chain signaling in MKN45 cells.
Topics: Actins; Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Cell Movement; Cisplatin; Cytoskeleton; Etoposide; Guanine Nucleotide Exchange Factors; Humans; Myosin Light Chains; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Phosphorylation; Rho Guanine Nucleotide Exchange Factors; rho-Associated Kinases; rhoA GTP-Binding Protein; Stomach Neoplasms; Vincristine | 2012 |
Local recurrence of gastric cancer after total gastrectomy: an unusual presentation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Etoposide; Fluorouracil; Gastrectomy; Humans; Levoleucovorin; Male; Neoplasm Recurrence, Local; Stomach Neoplasms; Tomography, X-Ray Computed | 2012 |
Successful treatment of gallbladder mixed adenoneuroendocrine carcinoma with neo-adjuvant chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carboplatin; Carcinoma, Neuroendocrine; Cystectomy; Etoposide; Female; Gallbladder Neoplasms; Hepatectomy; Humans; Immunohistochemistry; Liver Neoplasms; Lymph Node Excision; Middle Aged; Neoadjuvant Therapy; Neoplasms, Complex and Mixed; Octreotide; Paclitaxel; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Effects of morin on the pharmacokinetics of etoposide in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in female Sprague-Dawley rats.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Administration, Intravenous; Animals; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Cytochrome P-450 CYP3A; Drug Screening Assays, Antitumor; Etoposide; Female; Flavonoids; Gene Expression; Liver; Mammary Neoplasms, Experimental; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2013 |
Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Cisplatin; Dopa Decarboxylase; Dose-Response Relationship, Drug; Etoposide; Fluorouracil; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Leucovorin; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms | 2013 |
[A new combination therapy with low-dose FP and daily oral administration of low-dose etoposide--a report of 2 cases].
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Humans; Male; Quality of Life; Stomach Neoplasms | 2002 |
The role of MAPK pathways in the action of chemotherapeutic drugs.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Cycle; Ceramides; Enzyme Activation; Enzyme Inhibitors; Etoposide; Female; Flavonoids; HeLa Cells; Humans; Imidazoles; MAP Kinase Signaling System; Microtubules; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Paclitaxel; Pyridines; Skin Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2002 |
[Localization of primary small cell carcinoma with liver metastasis: a rare combination of colonic adenocarcinoma and undifferentiated small cell carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Colectomy; Colon; Colonic Neoplasms; Docetaxel; Doxorubicin; Etoposide; Female; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Neoplasms, Multiple Primary; Neoplasms, Unknown Primary; Paclitaxel; Taxoids; Time Factors; Vincristine | 2002 |
Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; DNA Damage; DNA-Binding Proteins; DNA, Neoplasm; Etoposide; Genetic Therapy; Humans; Male; Metribolone; Neoplasms, Hormone-Dependent; Plasmids; Poly(ADP-ribose) Polymerases; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Structure, Tertiary; Testosterone Congeners; Transfection; Tumor Cells, Cultured | 2002 |
Solitary esophageal metastasis of breast cancer after 11 years: a case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Deglutition Disorders; Diagnosis, Differential; Doxorubicin; Esophageal Neoplasms; Etoposide; Female; Humans; Immunohistochemistry; Lymphatic Metastasis; Magnetic Resonance Imaging; Middle Aged; Radiography; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2002 |
[A case of advanced gastric adenocarcinoma with mild elevation of serum SCC that responded remarkably to adjuvant chemotherapy of ADM, CDDP, ETP and 5-FU (ACVF)].
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Drug Administration Schedule; Drug Combinations; Etoposide; Fluorouracil; Gastrectomy; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Pyridines; Remission Induction; Serpins; Stomach Neoplasms; Tegafur | 2003 |
GL331 inhibits HIF-1alpha expression in a lung cancer model.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Northern; Blotting, Western; Electrophoretic Mobility Shift Assay; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Models, Biological; RNA, Messenger; Transcription Factors; Tumor Cells, Cultured | 2003 |
Bcl-w is expressed in a majority of infiltrative gastric adenocarcinomas and suppresses the cancer cell death by blocking stress-activated protein kinase/c-Jun NH2-terminal kinase activation.
Topics: Adenocarcinoma; Apoptosis Regulatory Proteins; Cell Death; Cell Survival; Enzyme Activation; Etoposide; fas Receptor; Humans; Hydrogen Peroxide; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neoplasm Staging; Protein Biosynthesis; Proteins; Stomach Neoplasms; Tumor Cells, Cultured | 2003 |
A novel carbazole topoisomerase II poison, ER-37328: potent tumoricidal activity against human solid tumors in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carbazoles; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Enzyme Inhibitors; Etoposide; Female; Humans; Lung Neoplasms; Macromolecular Substances; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Protein Binding; Pyrimidines; Stomach Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Chromones; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Morpholines; NF-kappa B; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Tumor Cells, Cultured | 2003 |
[The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells].
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Drug Interactions; Esophageal Neoplasms; Etoposide; Fluorouracil; Humans; Insulin; Lung Neoplasms; Tumor Cells, Cultured | 2003 |
Anti-tumour activity of Digitalis purpurea L. subsp. heywoodii.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Cardenolides; Cell Line, Tumor; Digitalis; Digoxin; Etoposide; Humans; Inhibitory Concentration 50; Kidney Neoplasms; Phytotherapy; Plant Extracts; Plant Leaves | 2003 |
The DNA damage-induced decrease of Bcl-2 is secondary to the activation of apoptotic effector caspases.
Topics: Adenocarcinoma; Adenoviridae; Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Apoptotic Protease-Activating Factor 1; Caspase Inhibitors; Caspases; Cell Transplantation; Dactinomycin; DNA Damage; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Enzyme Activation; Enzyme Inhibitors; Etoposide; Fibroblasts; Gene Deletion; Humans; Mice; Mice, SCID; Pancreatic Neoplasms; Proteins; Proto-Oncogene Proteins c-bcl-2; Transplantation, Heterologous; Tumor Cells, Cultured; Ultraviolet Rays | 2003 |
Prostate carcinoma presenting as multiple pulmonary nodules in an asymptomatic patient with a history of testicular nonseminomatous germ cell tumor.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Combined Modality Therapy; Etoposide; Flutamide; Humans; Leuprolide; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Orchiectomy; Postoperative Complications; Prostatic Neoplasms; Radiography; Testicular Neoplasms | 2003 |
[Simultaneous detection of both non-Hodgkin's lymphoma cells and breast cancer cells in pleural effusion--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Combinations; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Non-Hodgkin; Mastectomy, Segmental; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pleural Effusion; Prednisone; Tamoxifen; Tegafur; Uracil; Vincristine | 2003 |
Rectal adenocarcinoma with germ-cell differentiation: report of a case.
Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Transformation, Neoplastic; Cisplatin; Combined Modality Therapy; Etoposide; Fluorouracil; Germinoma; Humans; Liver Neoplasms; Male; Palliative Care; Rectal Neoplasms | 2003 |
Metastatic lung disease to the central nervous system: in vitro response to chemotherapeutic agents.
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Squamous Cell; Central Nervous System Neoplasms; Cisplatin; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Tumor Cells, Cultured | 2004 |
Bifocal esophageal and rectal cancer palliatively treated with argon plasma coagulation.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Argon; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease Progression; Doxorubicin; Esophageal Neoplasms; Etoposide; Fatal Outcome; Humans; Light Coagulation; Male; Microsurgery; Neoplasms, Second Primary; Palliative Care; Rectal Neoplasms | 2004 |
[Cellular changes in non-small cell lung cancer after neoadjuvant therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Diagnosis, Differential; Etoposide; Humans; Ifosfamide; Lung Neoplasms | 2004 |
A pilot study of neoadjuvant chemotherapy with mitomycin C, etoposide, cisplatin, and epirubicin for adenocarcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Hysterectomy; Lymphatic Metastasis; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Radiotherapy, Adjuvant; Statistics as Topic; Treatment Outcome; Uterine Cervical Neoplasms; Women's Health | 2004 |
[Development and characterization of a gemcitabine-resistant variant of human lung adenocarcinoma cell line A549].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Survival; Colony-Forming Units Assay; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Inhibitory Concentration 50; Lung Neoplasms; Vincristine | 2004 |
CD44 promotes resistance to apoptosis in human colon cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA Fragmentation; Drug Resistance, Neoplasm; Etoposide; Humans; Hyaluronan Receptors; Protein Isoforms; Transfection | 2004 |
Mobilization of peripheral blood stem cells (PBSCs) after etoposide, adriamycin and cisplatin therapy, and a multimodal cell therapy approach with PBSCs in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cancer Vaccines; Carcinoembryonic Antigen; Cell Line, Tumor; Cell Separation; Cisplatin; Combined Modality Therapy; Dendritic Cells; Doxorubicin; Etoposide; Flow Cytometry; Hematopoietic Stem Cell Mobilization; Humans; Immunotherapy; Lymphatic Metastasis; Male; Middle Aged; Neutrophils; Stem Cells; Stomach Neoplasms; Time Factors | 2004 |
Role of caveolin-1 in etoposide resistance development in A549 lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caveolin 1; Caveolins; Cell Membrane; Cholesterol; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2004 |
Adenosine triphosphate (ATP) enhances the antitumor effect of etoposide (VP16) in lung cancer cells.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Apoptosis; Drug Synergism; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2004 |
Retinoblastoma protein is required for efficient colorectal carcinoma cell apoptosis by histone deacetylase inhibitors in the absence of p21Waf.
Topics: Adenocarcinoma; Apoptosis; Butyrates; Cell Cycle Proteins; Cell Line, Tumor; Colony-Forming Units Assay; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; DNA, Neoplasm; Doxorubicin; Enzyme Inhibitors; Etoposide; Flow Cytometry; Gene Deletion; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kinetics; Retinoblastoma Protein; Transfection | 2005 |
Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Staging; Treatment Outcome; Vindesine | 2005 |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Modification of thermosensitivity by amrubicin or amrubicinol in human lung adenocarcinoma A549 cells and the kinetics of apoptosis and necrosis induction.
Topics: Adenocarcinoma; Anthracyclines; Apoptosis; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Synergism; Etoposide; Hot Temperature; Humans; Lung Neoplasms; Necrosis; Time Factors | 2005 |
Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms; Combined Modality Therapy; Disease Models, Animal; Etoposide; Mice; Mice, Inbred BALB C; Radiotherapy | 2005 |
Erybraedin C and bitucarpin A, two structurally related pterocarpans purified from Bituminaria bituminosa, induced apoptosis in human colon adenocarcinoma cell lines MMR- and p53-proficient and -deficient in a dose-, time-, and structure-dependent fashion
Topics: Adenocarcinoma; Apoptosis; Cell Division; Cell Line, Tumor; Colonic Neoplasms; DNA-Binding Proteins; Dose-Response Relationship, Drug; Etoposide; Fabaceae; Humans; MutS Homolog 3 Protein; Pterocarpans; Structure-Activity Relationship; Thioguanine; Tumor Suppressor Protein p53 | 2006 |
Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Azepines; Cell Division; Chemotherapy, Adjuvant; Etoposide; Humans; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Myosin-Light-Chain Kinase; Naphthalenes; Prostatic Neoplasms; Random Allocation; Rats | 2006 |
Differential susceptibility to etoposide in clones derived from a human ovarian cancer cell line.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Cell Line, Tumor; Clone Cells; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Neoplasm; Etoposide; Female; Flow Cytometry; Humans; Ovarian Neoplasms; Proto-Oncogene Proteins c-bcl-2; Signal Transduction | 2006 |
Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Cells, Cultured; Ceramides; Cytochromes c; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Etoposide; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Male; Membrane Potential, Mitochondrial; Neoplasms, Hormone-Dependent; Prostate; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2007 |
Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase Inhibitors; Caspases; Cell Adhesion; Cell Line, Tumor; Drug Resistance, Neoplasm; Etoposide; Humans; Interleukin-1beta; Neural Cell Adhesion Molecule L1; Nitric Oxide; Nitric Oxide Synthase Type II; Pancreatic Neoplasms; Tumor Cells, Cultured | 2007 |
[Survival status of stage IV non-small cell lung cancer patients after radiotherapy--a report of 287 cases].
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Particle Accelerators; Radioisotope Teletherapy; Radiotherapy, Conformal; Radiotherapy, High-Energy; Retrospective Studies; Survival Analysis | 2006 |
[A case of non-small cell lung cancer in which complete response was achieved with chemotherapy including cisplatin, vinorelbine, mitomycin C, followed by additional cisplatin, etoposide and concurrent radiotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Male; Mitomycin; Neoplasm Staging; Pneumonectomy; Remission Induction; Vinblastine; Vinorelbine | 2006 |
Endometrial cancer cell survival and apoptosis is regulated by protein kinase C alpha and delta.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Cell Survival; Endometrial Neoplasms; Etoposide; Female; Humans; Immunoenzyme Techniques; Immunoprecipitation; Poly(ADP-ribose) Polymerases; Protein Kinase C-alpha; Protein Kinase C-delta; Subcellular Fractions; Tumor Cells, Cultured | 2006 |
Ethylenediaminetetraacetic acid affects subcellular expression of clusterin protein in human colon adenocarcinoma COLO 205 cell line.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Calcium; Cell Line, Tumor; Cell Survival; Chelating Agents; Clusterin; Colorectal Neoplasms; Edetic Acid; Etoposide; Homeostasis; Humans; Molecular Biology; Protein Isoforms | 2007 |
Chemotherapy and zoledronate sensitize solid tumour cells to Vgamma9Vdelta2 T cell cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Burkitt Lymphoma; Carcinoma; Cell Line, Tumor; Cisplatin; Colorectal Neoplasms; Concanavalin A; Cytotoxicity, Immunologic; Diphosphonates; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Genes, T-Cell Receptor delta; Genes, T-Cell Receptor gamma; Humans; Imidazoles; Interferon-gamma; Lovastatin; Lung Neoplasms; Male; Membrane Glycoproteins; Neoplasms; Perforin; Pore Forming Cytotoxic Proteins; Prostatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Urinary Bladder Neoplasms; Vincristine; Zoledronic Acid | 2007 |
[Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Fluorouracil; Humans; Lactones; Pyrazoles; Stomach Neoplasms; Sulfonamides; Sulfones | 2007 |
[Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Survival Rate | 2007 |
Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Docetaxel; Estramustine; Etoposide; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nephrostomy, Percutaneous; Nitriles; Phenotype; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds; Transurethral Resection of Prostate; Urinary Diversion | 2007 |
Oral etoposide-induced leucocytoclastic vasculitis in a patient with lung carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Vasculitis, Leukocytoclastic, Cutaneous | 2007 |
Expression of androgen receptor is negatively regulated by p53.
Topics: 5' Untranslated Regions; Adenocarcinoma; Androgens; Bone Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; Consensus Sequence; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Male; Neoplasms, Hormone-Dependent; Osteosarcoma; Promoter Regions, Genetic; Prostatic Neoplasms; Receptors, Androgen; RNA, Small Interfering; Transfection; Tumor Suppressor Protein p53 | 2007 |
[Primary neuroendocrine carcinoma of the liver. From carcinoid tumor to small-cell hepatic carcinoma: case reports and review of the literature].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoid Tumor; Carcinoma; Carcinoma, Neuroendocrine; Cell Differentiation; Etoposide; Female; Follow-Up Studies; Humans; Liver Neoplasms; Rectal Neoplasms; Risk Factors; Treatment Outcome | 2008 |
Inhibition of MDR1 expression by retinol treatment increases sensitivity to etoposide (VP16) in human neoplasic cell line.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation; HT29 Cells; Humans; Polymerase Chain Reaction; Vitamin A | 2008 |
Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Salvage Therapy; Survival Analysis | 2008 |
Feasibility of high dose VP 16-213 as single agent or in combination with cyclophosphamide and autologous bone marrow transplantation (ABMT).
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Podophyllotoxin | 1984 |
Cisplatin and etoposide combination in the treatment of bronchogenic carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Humans; Lung Neoplasms; Middle Aged | 1984 |
Cis-dichlorodiammineplatinum (II) and VP 16-213 combination chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Female; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1981 |
[Results of drug therapy of inoperable non-small cell lung carcinoma with VP 16-213 (Etoposide) and cis-platin. A phase II study].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1983 |
[Effect of etoposide for pulmonary metastases from urogenital tract cancer].
Topics: Adenocarcinoma; Administration, Oral; Aged; Carcinoma, Transitional Cell; Etoposide; Humans; Infusions, Parenteral; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Prostatic Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms | 1984 |
Phase II trial of etoposide in the management of advanced or recurrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Evaluation; Etoposide; Female; Humans; Middle Aged; Podophyllotoxin; Uterine Cervical Neoplasms | 1984 |
cis-Platinum (DDP) and VP 16-213 (etoposide) combination chemotherapy for advanced non-small cell lung cancer. A phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pulmonary Atelectasis; Time Factors | 1984 |
Chemotherapy for advanced adenocarcinoma and squamous cell carcinoma of the lung with etoposide and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Thrombocytopenia | 1984 |
Warfarin, etoposide, and vindesine interactions.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Interactions; Etoposide; Humans; Lung Neoplasms; Male; Prothrombin Time; Vinblastine; Vindesine; Warfarin | 1984 |
Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents.
Topics: Adenocarcinoma; Animals; Cell Survival; Colonic Neoplasms; Etoposide; Humans; Leukemia P388; Leukemia, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Podophyllotoxin; Skin Ulcer; Solvents; Teniposide; Tumor Stem Cell Assay | 1983 |
Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship.
Topics: Adenocarcinoma; Cell Line; Cell Survival; DNA; DNA Repair; Etoposide; Humans; Kinetics; Lung Neoplasms; Podophyllotoxin; Structure-Activity Relationship; Teniposide | 1984 |
Phase II trial of etoposide in adenocarcinomas of the upper gastrointestinal tract.
Topics: Adenocarcinoma; Adult; Aged; Drug Evaluation; Etoposide; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Podophyllotoxin | 1983 |
Response of the Dunning R3327H prostatic adenocarcinoma to radiation and various chemotherapeutic drugs.
Topics: Adenocarcinoma; Animals; Cisplatin; Estramustine; Etoposide; Female; Male; Neoplasm Transplantation; Prostatic Neoplasms; Rats; Vincristine | 1982 |
Etoposide alone and in combination with cyclophosphamide, adriamycin and cis-platinum in patients with Mo and Mi non-small-cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Podophyllotoxin | 1982 |
Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium).
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Middle Aged; Podophyllotoxin | 1982 |
Phase II studies in advanced, recurrent pelvic malignancies: conducted by the Gynecologic Oncology Group, Experimental Design and Experience.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Dianhydrogalactitol; Drug Evaluation; Etoposide; Female; Humans; Maytansine; Neoplasm Recurrence, Local; Pelvic Neoplasms; Piperazines; Razoxane; Research Design; Triazines | 1982 |
VP-16 and adriamycin in patients with advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Fluorouracil; Humans; Leukopenia; Male; Methotrexate; Middle Aged; Podophyllotoxin; Prednisone; Thrombocytopenia; Vincristine; Vomiting | 1982 |
Phase II trial of VP-16-213 in non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Squamous Cell; Digestive System; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1982 |
[Chemotherapy of non-small-cell bronchial cancer with a combination of Cis-diamminedichloroplatinum (II) and VP 16-213].
Topics: Adenocarcinoma; Body Weight; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Etoposide; Humans; Leukocyte Count; Lung Neoplasms; Podophyllotoxin; Vomiting | 1981 |
[A case of gastric cancer responding well to MTX/5-FU (methotrexate/5-fluorouracil) and PMUE (CDDP, MMC, UFT, etoposide) therapies upon lymphnode recurrence].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Etoposide; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Mitomycin; Stomach Neoplasms; Tegafur; Uracil | 1995 |
[A case of teratoma of the testis with retroperitoneal lymph nodes involved with malignant teratoma after chemotherapy].
Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Transformation, Neoplastic; Cisplatin; Etoposide; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Teratoma; Testicular Neoplasms | 1993 |
[Experimental and clinical study on chemotherapy for cervical adenocarcinoma].
Topics: Aclarubicin; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dactinomycin; Drug Administration Schedule; Etoposide; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mitomycin; Neoplasm Transplantation; Uterine Cervical Neoplasms | 1995 |
Adenocarcinoma of the testis--lack of response to conventional chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Humans; Male; Middle Aged; Testicular Neoplasms | 1993 |
[Etoposide, epirubicin and cisplatin (EEP) combination in metastatic cancers of the cardia and the stomach. Groupe de recherche en cancérologie du Nord (GRECNO)].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Epirubicin; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome | 1994 |
Severe, disabling neurologic toxicity following cisplatin retreatment.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases; Cerebrovascular Disorders; Cisplatin; Cognition Disorders; Combined Modality Therapy; Etoposide; Female; Humans; Lung Neoplasms | 1995 |
MCF-7 human mammary adenocarcinoma cell death in vitro in response to hormone-withdrawal and DNA damage.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Death; Cell Division; Cell Survival; DNA Damage; DNA, Neoplasm; Estradiol; Estrogen Antagonists; Estrogens; Etoposide; Fulvestrant; Humans; Mechlorethamine; Neoplasms, Hormone-Dependent; Tumor Cells, Cultured | 1995 |
Effects of single and combined application of anti-cancer drugs on cervical adenocarcinoma. I. Antitumor activity in vitro.
Topics: Adenocarcinoma; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Combined Modality Therapy; Etoposide; Female; Humans; In Vitro Techniques; Interferon-gamma; Mice; Mice, Nude; Middle Aged; Mitomycin; Neoplasms, Experimental; Recombinant Proteins; Uterine Cervical Neoplasms | 1995 |
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Blotting, Southern; Carcinoma; Chromosome Aberrations; Chromosome Disorders; Cisplatin; Etoposide; Female; Germinoma; Humans; Ifosfamide; In Situ Hybridization, Fluorescence; Karyotyping; Lymphoma; Male; Mediastinal Neoplasms; Middle Aged; Neoplasms, Unknown Primary; Neuroectodermal Tumors, Primitive, Peripheral; Prospective Studies; Retroperitoneal Neoplasms; Testicular Neoplasms; Treatment Outcome | 1995 |
[Treatment of recurrent uterine endometrial cancer in adjuvant therapy with medroxyprogesterone acetate (MPA) in addition of etoposide].
Topics: Adenocarcinoma; Administration, Oral; Aged; Drug Administration Schedule; Endometrial Neoplasms; Etoposide; Female; Humans; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local | 1995 |
High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bone Marrow Transplantation; Breast Neoplasms; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Staging; Remission Induction; Risk Factors; Survival Rate; Transplantation, Autologous | 1994 |
Five-drug combination chemotherapy (FAPEL) for advanced gastric cancer: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Pilot Projects; Stomach Neoplasms | 1994 |
[A case report: ovarian carcinoma IVth can become complete remission by immunochemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Immunotherapy; Infusion Pumps, Implantable; Neoplasm Staging; Ovarian Neoplasms; Picibanil; Remission Induction | 1994 |
[A case of cutaneous and brain metastasis of gastric carcinoma, treated effectively by chemotherapy with CDDP, MMC, etoposide and 5'-DFUR].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Drug Administration Schedule; Etoposide; Female; Floxuridine; Humans; Infusions, Intravenous; Mitomycin; Neoplasm Invasiveness; Skin Neoplasms; Stomach Neoplasms; Treatment Outcome | 1994 |
[A case of curatively operated gastric cancer with peritonitis carcinomatosa treated by intraperitoneal administration of CDDP.Etoposide and EAP therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Gastrectomy; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Peritonitis; Stomach Neoplasms | 1994 |
Oral etoposide in the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Drug Administration Schedule; Drug Resistance; Etoposide; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Remission Induction; Survival Rate | 1994 |
[Chemotherapy for metastatic brain tumors with CDDP and other agents: correlation between chemotherapeutic effects and the results of in vitro chemosensitivity tests using collagen gel-embedded culture combined with computerized image analysis in metastat
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Collagen; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Tumor Cells, Cultured; Vindesine | 1994 |
Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Topics: Adenocarcinoma; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Colonic Neoplasms; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Resistance; Etoposide; Flow Cytometry; Humans; Leukemia L1210; Lung Neoplasms; Membrane Glycoproteins; Mice; Novobiocin; Tumor Cells, Cultured | 1993 |
Endoscopic ultrasonography in the quantitative assessment of response to chemotherapy in patients with adenocarcinoma of the esophagus and esophagogastric junction.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barium Sulfate; Cisplatin; Doxorubicin; Esophageal Neoplasms; Esophagogastric Junction; Esophagus; Etoposide; Humans; Radiography; Ultrasonography | 1993 |
Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Time Factors; Treatment Failure | 1993 |
[Four cases of advanced adenocarcinoma showing marked response to EAP (etoposide, ADM, CDDP) treatment].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Doxorubicin; Etoposide; Female; Gallbladder Neoplasms; Humans; Male; Middle Aged; Rectal Neoplasms; Remission Induction | 1993 |
[Combination chemotherapy with carboplatin and etoposide against lung adenocarcinoma in a patient undergoing hemodialysis: a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged; Renal Dialysis | 1993 |
Etoposide-resistant human colon and lung adenocarcinoma cell lines exhibit sensitivity to homoharringtonine.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Colonic Neoplasms; Drug Resistance; Etoposide; Harringtonines; Homoharringtonine; Humans; Lung Neoplasms; Tumor Cells, Cultured | 1993 |
[Treatment of unresectable non-small cell lung cancer (NSCLC) with carboplatin and chronic daily administration of oral etoposide].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged | 1994 |
[Successful treatment of two patients with advanced gastric cancer by neoadjuvant chemotherapy with EAP regimen].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Hepatic Artery; Humans; Infusion Pumps, Implantable; Liver Neoplasms; Male; Middle Aged; Stomach Neoplasms | 1994 |
Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Male; Postoperative Complications; Prospective Studies; Radiotherapy Dosage; Survival Rate | 1993 |
[In vitro comparison of podophyllotoxin analogues; etoposide, teniposide and NK 611 using human lung cancer cell lines].
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Division; Drug Resistance; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Podophyllotoxin; Teniposide; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1993 |
Interferon-alpha and interferon-gamma combined with chemotherapy: in vitro sensitivity studies in non-small cell lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Humans; Interferon Type I; Interferon-gamma; Lung Neoplasms; Recombinant Proteins; Tumor Cells, Cultured | 1993 |
[Antiemetic efficacy of granisetron in patients receiving 5-day continuous infusion of cisplatin].
Topics: Adenocarcinoma; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granisetron; Humans; Indazoles; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Nausea; Vindesine; Vomiting | 1993 |
Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Etoposide; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1993 |
Respiratory failure due to pulmonary lymphangitis carcinomatosis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Male; Middle Aged; Respiratory Insufficiency | 1993 |
[Etoposide, pirarubicin and cisplatin(ETP) combined therapy of inoperable head and neck cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged | 1993 |
Endometrioid carcinoma of the ovary. Retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Endometriosis; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Medroxyprogesterone; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Retrospective Studies; Survival Rate; Tamoxifen | 1993 |
Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; DNA, Neoplasm; Drug Screening Assays, Antitumor; Estramustine; Etoposide; In Vitro Techniques; Male; Nuclear Matrix; Prostate; Prostatic Neoplasms; Rats; Tumor Cells, Cultured | 1993 |
Epirubicin, etoposide and cisplatin in advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Etoposide; Humans; Male; Middle Aged; Pancreatic Neoplasms | 1993 |
Patient experiences adverse drug reaction to etoposide for adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Drug Hypersensitivity; Etoposide; Humans; Lung Neoplasms; Male | 1995 |
Biomodulation by hyperthermia of topoisomerase II-targeting drugs in human colorectal cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Colorectal Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Hot Temperature; Humans; Neoplasm Proteins; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vincristine | 1995 |
The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Division; Cisplatin; Dacarbazine; Drug Screening Assays, Antitumor; Etoposide; Fluorouracil; Humans; Melanoma; Mice; Mice, Nude; Rectal Neoplasms; Tirapazamine; Transplantation, Heterologous; Triazines | 1996 |
[Clinical implication of p53 analysis on DNA-damaging therapies of human gastric and rectal cancers].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cisplatin; DNA Damage; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Rectal Neoplasms; Stomach Neoplasms; Tumor Suppressor Protein p53 | 1996 |
Quantitative immunocytochemical assays of topoisomerase II in lung adenocarcinoma cell lines. Correlation to topoisomerase II alpha content and topoisomerase II catalytic activity.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antibodies, Neoplasm; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Blotting, Western; Bronchoalveolar Lavage Fluid; Catalysis; Coloring Agents; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Kinetoplast; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Flow Cytometry; Humans; Immunohistochemistry; Isoenzymes; Lung Neoplasms; Tumor Cells, Cultured | 1996 |
[Effect of calmodulin antagonist on chemosensitivity of primary cultured lung cancer cells].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Calmodulin; Carcinoma, Squamous Cell; Doxorubicin; Drug Synergism; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Trifluoperazine; Tumor Cells, Cultured; Vincristine | 1995 |
Secondary acute myelogenous leukemia following treatment with oral etoposide.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Etoposide; Humans; Leukemia, Myeloid, Acute; Male; Neoplasms, Second Primary; Prostatic Neoplasms | 1996 |
[A case of advanced gastric cancer with multiple liver metastasis successfully treated with combination chemotherapy using UFT, CDDP and etoposide].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Drug Combinations; Etoposide; Humans; Injections, Intravenous; Lentinan; Leukopenia; Liver Neoplasms; Male; Nausea; Stomach Neoplasms; Tegafur; Thrombocytopenia; Uracil | 1996 |
[A pilot study of low dose etoposide therapy for recurrenced prostate cancer in complicated over 75 years old stage D2 cases].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Neoplasms; Drug Administration Schedule; Etoposide; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Prostatic Neoplasms | 1996 |
Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study.
Topics: Adenocarcinoma; Adult; Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Survival Analysis | 1997 |
Topoisomerase II alpha content and topoisomerase II catalytic activity cannot explain drug sensitivities to topoisomerase II inhibitors in lung cancer cell lines.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Humans; Isoenzymes; Lung Neoplasms; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
[Early results of chemotherapy in patients with non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Treatment Outcome | 1996 |
Indomethacin enhances the cytotoxicity of VCR and ADR in human pulmonary adenocarcinoma cells.
Topics: Adenocarcinoma; Adjuvants, Pharmaceutic; Coloring Agents; Doxorubicin; Drug Combinations; Drug Screening Assays, Antitumor; Etoposide; Humans; Indomethacin; Lung Neoplasms; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured; Vincristine | 1997 |
DNase I primary transcript is alternatively spliced in both normal and apoptotic cells: no evidence of up-regulation in apoptosis.
Topics: 3T3 Cells; Adenocarcinoma; Alternative Splicing; Animals; Apoptosis; Breast Neoplasms; Cell Line; Deoxyribonuclease I; Etoposide; Exons; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Jurkat Cells; Liver Neoplasms, Experimental; Male; Mice; PC12 Cells; Polymerase Chain Reaction; Prostatic Neoplasms; Rats; Transcription, Genetic; Tumor Cells, Cultured; Up-Regulation | 1997 |
Multimodality treatment in the management of esophageal cancer: neoadjuvant chemoradiotherapy followed by transhiatal esophagectomy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Etoposide; Female; Fluorouracil; Humans; Male; Middle Aged; Radiotherapy, Adjuvant; Treatment Outcome | 1997 |
Neuron-specific enolase (NSE) serum level in non small cell lung cancer--can it be an indicator of tumour chemosensitivity?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Differentiation; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Phosphopyruvate Hydratase; Predictive Value of Tests; Treatment Outcome; Vincristine | 1997 |
[Histopathological effect of neoadjuvant chemohormonal therapy for prostatic cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diethylstilbestrol; Etoposide; Gonadotropin-Releasing Hormone; Humans; Male; Prostatectomy; Prostatic Neoplasms; Treatment Outcome | 1997 |
Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Humans; Indenes; Indoles; Irinotecan; Lung Neoplasms; Male; Melanoma; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Neoplasms, Experimental; Pyridines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1997 |
Role of the vacuolar H+-ATPase in daunorubicin distribution in etoposide-resistant MCF7 cells overexpressing the multidrug-resistance associated protein.
Topics: 4-Chloro-7-nitrobenzofurazan; Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Cell Nucleus; Cholesterol; Cytoplasm; Daunorubicin; Drug Resistance, Multiple; Etoposide; Female; Humans; Norsteroids; Proton-Translocating ATPases; Tumor Cells, Cultured; Vacuolar Proton-Translocating ATPases; Verapamil | 1998 |
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Cell Separation; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; DNA Repair; DNA, Neoplasm; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Melphalan; Paclitaxel; Tamoxifen; Thioguanine; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1998 |
Growth characteristics and metastatic properties of human breast cancer xenografts in immunodeficient mice.
Topics: Adenocarcinoma; Aged; Animals; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Etoposide; Female; Humans; Injections, Intravenous; Injections, Subcutaneous; Lymphatic Metastasis; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Transplantation; Polymerase Chain Reaction; Severe Combined Immunodeficiency; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
[Advanced gastric cancer curatively resected following combined neoadjuvant chemotherapy--report of a case].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Fluorouracil; Humans; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Stomach Neoplasms | 1998 |
Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Multiple; Drug Screening Assays, Antitumor; Etoposide; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Vault Ribonucleoprotein Particles | 1998 |
Pre-operative sequential chemo- and radiochemotherapy in locally advanced carcinomas of the lower oesophagus and gastro-oesophageal junction.
Topics: Adenocarcinoma; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagogastric Junction; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Preoperative Care; Survival Analysis; Treatment Outcome | 1998 |
Neoadjuvant chemotherapy with mitomycin C, etoposide, and cisplatin for adenocarcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Humans; Middle Aged; Mitomycin; Neoplasm Staging; Uterine Cervical Neoplasms | 1998 |
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carrier Proteins; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; DNA Adducts; DNA Damage; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Fluorouracil; Humans; Melphalan; Methylnitronitrosoguanidine; Mutagenesis; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Thioguanine; Tumor Cells, Cultured | 1997 |
Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Mice; Mice, Inbred CBA; Neoplasm Transplantation; Rhabdomyosarcoma; Transplantation, Heterologous | 1996 |
Effect of Tween-80 on cell killing by etoposide in human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Humans; Lung Neoplasms; Polysorbates; Surface-Active Agents; Tumor Cells, Cultured | 1999 |
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Cell Separation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Flow Cytometry; Fluorescent Antibody Technique, Indirect; Genes, p53; Humans; Lung Neoplasms; Mutation | 1999 |
Effect of vesnarinone in combination with anti-cancer drugs on lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Division; Cisplatin; Coloring Agents; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Pyrazines; Quinolines; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1999 |
[A case report: modified PMUE therapy might be effective for advanced gastric carcinoma with pulmonary carcinomatous lymphangitis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Stomach Neoplasms | 1999 |
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cell Cycle; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Protein Processing, Post-Translational; Receptor, ErbB-2; Recombinant Proteins; Thiotepa; Topoisomerase II Inhibitors; Transplantation, Heterologous; Trastuzumab; Treatment Outcome; Vinblastine | 1999 |
Pharmacokinetics of etoposide after intrathoracic instillation to lung cancer patients with pleural effusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Chromatography, High Pressure Liquid; Etoposide; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pleural Effusion, Malignant | 1999 |
Vasospastic angina likely related to cisplatin-containing chemotherapy and thoracic irradiation for lung cancer.
Topics: Adenocarcinoma; Aged; Angina Pectoris, Variant; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Electrocardiography; Etoposide; Heart; Humans; Lung Neoplasms; Male; Middle Aged; Myocardial Ischemia; Neoplasm Staging; Radiation Injuries; Radiotherapy; Vindesine | 1999 |
[A case of lung cancer with hypercalcemia and renal failure responsive to pamidronate].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diphosphonates; Etoposide; Humans; Hypercalcemia; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Protein Biosynthesis; Renal Insufficiency | 1999 |
[Evaluation of antitumor activity of etoposide administered orally for 21 consecutive days against human uterine cancer subcutaneous and/or orthotopic xenografts in nude mice].
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Floxuridine; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Skin; Transplantation, Heterologous; Uterine Neoplasms | 1999 |
Regulation of BAX and BCL-2 expression in breast cancer cells by chemotherapy.
Topics: Adenocarcinoma; Annexin A5; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Cell Cycle; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Estrogens; Etoposide; Female; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1999 |
Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Combined Modality Therapy; Drug Therapy, Combination; Etoposide; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Prognosis; Retrospective Studies; Stomach; Stomach Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 1999 |
[A case of stage IVb (H2P0N4T4) gastric cancer successfully treated with neoadjuvant chemotherapy (PMFE therapy)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Fluorouracil; Gastrectomy; Humans; Male; Mitomycin; Neoadjuvant Therapy; Remission Induction; Stomach Neoplasms; Tegafur; Uracil | 2000 |
Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Survival Analysis; Vinblastine | 1999 |
Management of patients with cancer of unknown primary site.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma; Etoposide; Evaluation Studies as Topic; Female; Humans; Male; Neoplasms, Unknown Primary; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2000 |
[Histoculture drug response assay on non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mitomycin; Tumor Cells, Cultured | 2000 |
Effect of adjuvant chemotherapy using pirarubicin, cisplatin, and etoposide (PEP) for stage IVB endometrial carcinoma: a case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Endometrial Neoplasms; Etoposide; Female; Humans; Middle Aged; Neoplasm Staging | 2000 |
Immunohistochemical expression of glutathione transferase-pi in untreated primary non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Etoposide; Female; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Immunohistochemistry; Isoenzymes; Lung Neoplasms; Male; Middle Aged; Time Factors | 2000 |
Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis.
Topics: Adenocarcinoma; Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Breast Neoplasms; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 8; Caspase 9; Caspases; Cysteine Proteinase Inhibitors; Enzyme Activation; Enzyme Precursors; Etoposide; fas Receptor; Humans; Intracellular Signaling Peptides and Proteins; Jurkat Cells; Mitochondria; Mitomycin; Neoplasm Proteins; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2000 |
A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells.
Topics: Adenocarcinoma; Animals; Apoptosis; Casein Kinase II; Catalytic Domain; Cell Compartmentation; Cytoprotection; Cytosol; Diethylstilbestrol; DNA, Neoplasm; Etoposide; Female; Humans; Male; Mammary Neoplasms, Animal; Mice; Nuclear Matrix; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein Transport; Recombinant Proteins; Subcellular Fractions | 2001 |
Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Etoposide; Female; Follow-Up Studies; Humans; Interleukin-2; Life Tables; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Remission Induction; Survival Analysis; Th1 Cells; Treatment Outcome | 2000 |
Identification of chromosomal loci associated with non-P-glycoprotein-mediated multidrug resistance to topoisomerase II inhibitor in lung adenocarcinoma cell line by comparative genomic hybridization.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Southern; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Genetic Markers; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Lung Neoplasms; Nucleic Acid Hybridization; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2001 |
[Three cases of liver metastasis of colon cancer responding to systemic combination chemotherapy utilizing CPT-11].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Irinotecan; Liver Neoplasms; Male; Tegafur; Uracil | 2000 |
Advanced adenocarcinoma of the urinary bladder successfully treated by the combination of cisplatinum, mitomycin-C, etoposide and tegafur-uracil chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Middle Aged; Mitomycin; Neoplasm Staging; Remission Induction; Tegafur; Urinary Bladder Neoplasms | 2001 |
[Curative resection of advanced gastric cancer responding to preoperative chemotherapy--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Fluorouracil; Gastrectomy; Humans; Infusion Pumps, Implantable; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Stomach Neoplasms | 2001 |
p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents.
Topics: Adenocarcinoma; Alleles; Amino Acid Chloromethyl Ketones; Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Benzothiazoles; Butyrates; Cisplatin; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Proteinase Inhibitors; Demecolcine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Intracellular Membranes; Membrane Potentials; Mitochondria; Neoplasm Proteins; Recombination, Genetic; Resveratrol; Stilbenes; Thiazoles; Toluene; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Differential regulation of phosphatidylserine externalization and DNA fragmentation by caspases in anticancer drug-induced apoptosis of rat mammary adenocarcinoma MTLn3 cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Cisplatin; DNA Fragmentation; Doxorubicin; Etoposide; Exocytosis; Mammary Neoplasms, Animal; Necrosis; Phosphatidylserines; Rats; Tumor Cells, Cultured | 2001 |
[Outpatient chemotherapy for advanced lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Docetaxel; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2001 |
Modification of the sensitivity to cisplatin with c-myc over-expression or down-regulation in colon cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Division; Cisplatin; Colonic Neoplasms; DNA Damage; DNA Primers; Drug Resistance, Neoplasm; Etoposide; Humans; In Situ Nick-End Labeling; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-myc; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Transfection; Tumor Cells, Cultured | 2001 |
Twelve-year follow-up of trimodality therapy for stage IIIA non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome | 2001 |
Primary gastric choriocarcinoma: a case report and review of the literature.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Choriocarcinoma; Chorionic Gonadotropin, beta Subunit, Human; Cisplatin; Diagnosis, Differential; Etoposide; Fatal Outcome; Female; Gastrointestinal Hemorrhage; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Salvage Therapy; Stomach Neoplasms; Tomography, X-Ray Computed | 2001 |
Management of a 16-year-old boy with adenocarcinoma at the esophageal gastric junction.
Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diagnosis, Differential; Doxorubicin; Esophagogastric Junction; Etoposide; Fluorouracil; Humans; Male; Methotrexate; Paclitaxel; Stomach Neoplasms | 2001 |
Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status.
Topics: Adenocarcinoma; Binding Sites; Breast Neoplasms; Cell Nucleolus; Cell Nucleus; DNA Topoisomerases, Type I; Etoposide; Female; Genes, p53; Humans; Peptide Fragments; Polymerase Chain Reaction; Recombinant Fusion Proteins; Transcription, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Lactic Acidosis in Non-Hodgkin's Lymphoma and response to Chemotherapy.
Topics: Acidosis, Lactic; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Colonic Neoplasms; Cyclophosphamide; Doxorubicin; Etoposide; Fatal Outcome; Humans; Lactates; Liver; Lymphoma, Large B-Cell, Diffuse; Male; Neoplasms, Second Primary; Prednisone; Sodium Bicarbonate; Vincristine | 2002 |
[A gastric cancer patient with marked para-aortic lymph node metastasis surviving more than 10 years after aggressive operation and repeated EAP chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Stomach Neoplasms; Survivors | 2002 |
Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; bcl-X Protein; Camptothecin; Collagen; Colonic Neoplasms; Enzyme Inhibitors; Etoposide; Extracellular Matrix; Extracellular Matrix Proteins; Fibroblasts; Fibronectins; Fluorouracil; Genes, bcl-2; Hepatocytes; Humans; Neoplasm Proteins; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Inbred F344; Rats, Wistar; Stromal Cells; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2002 |
The chemotherapy of metastatic gastric adenocarcinomas with hypersecretion of alpha-fetoprotein or beta-human chorionic gonadotrophin: report of two cases.
Topics: Adenocarcinoma; Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chorionic Gonadotropin, beta Subunit, Human; Drug Resistance, Neoplasm; Etoposide; Humans; Liver Neoplasms; Male; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis | 2002 |
[Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors].
Topics: Adenocarcinoma; Bronchial Neoplasms; Carcinoma; Carcinoma, Small Cell; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Podophyllotoxin; Prostatic Neoplasms; Remission, Spontaneous | 1975 |
VP-16, cyclophosphamide, adriamycin and cis-platinum (V:CAP-I) in patients with metastatic adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Podophyllotoxin; Remission, Spontaneous; Time Factors; Vomiting | 1979 |
VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin; Time Factors | 1978 |
[VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].
Topics: Adenocarcinoma; Anaplasia; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Lung Neoplasms; Methotrexate; Neoplasm Metastasis; Podophyllotoxin; Remission, Spontaneous; Vincristine | 1977 |
Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Northern; Blotting, Southern; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line; Cell Survival; Cisplatin; DNA Topoisomerases, Type II; DNA, Neoplasm; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Fluorouracil; Humans; Lung Neoplasms; Phenotype; Restriction Mapping; RNA, Neoplasm; Teniposide | 1992 |
[Pilot phase II trial of high-dose etoposide combined with cisplatin in the treatment of refractory lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Sarcoma | 1992 |
Chemotherapy as initial treatment for cervical carcinoma: clinical and tumor marker response.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Middle Aged; Serpins; Trypsin Inhibitor, Kazal Pancreatic; Uterine Cervical Neoplasms | 1992 |
[The effect of combination chemotherapy with cisplatin, vincristine, doxorubicin and etoposide (Tokushima-CODE: T-CODE) against lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Humans; Lung Neoplasms; Middle Aged; Pilot Projects; Vincristine | 1992 |
Phase II study of cisplatin, ifosfamide with mesna, and etoposide (PIE) chemotherapy for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Protocols; Clinical Trials, Phase II as Topic; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Middle Aged; Remission Induction; Survival Rate | 1992 |
Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Topics: Adenocarcinoma; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; DNA; DNA Topoisomerases, Type II; Drug Synergism; Etoposide; Humans; Leukemia; Lung Neoplasms; Novobiocin; RNA; Teniposide; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1992 |
The role of cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Clinical Protocols; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Neoplasms, Unknown Primary; Remission Induction; Salvage Therapy; Survival Rate; Vinblastine | 1992 |
[A case of adenocarcinoma of lung cancer with multiple brain metastasis and lymphangitis carcinomatosa responding well to chemotherapy with carboplatin, etoposide and ifosfamide].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Lymphangitis; Male; Radiotherapy Dosage | 1992 |
[A case of gastric carcinoma with peritonitis carcinomatosa responding remarkably to etoposide, adriamycin and cisplatin (EAP) therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; Doxorubicin; Etoposide; Humans; Infusions, Intravenous; Male; Middle Aged; Peritonitis; Stomach Neoplasms | 1992 |
Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Remission Induction | 1992 |
Cisplatin in combination with continuous VP16 infusion as second line chemotherapy in ovarian carcinoma. A pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Pilot Projects; Recurrence; Treatment Outcome | 1992 |
Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity.
Topics: Adenocarcinoma; Adult; Animals; Colonic Neoplasms; Cyclosporins; Drug Administration Schedule; Drug Interactions; Drug Screening Assays, Antitumor; Etoposide; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Specific Pathogen-Free Organisms | 1992 |
Esophageal carcinoma: esophageal ultrasound assessment of preoperative chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; Esophageal Neoplasms; Esophagoscopy; Esophagus; Etoposide; Humans; Male; Middle Aged; Ultrasonography | 1992 |
[A case of gallbladder cancer with marked response to EAP treatment].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration Schedule; Etoposide; Gallbladder Neoplasms; Humans; Male; Middle Aged | 1992 |
[Characterization of two novel cell lines established from a single human uterine cervical adenocarcinoma, and their chemosensitivities and hormonal effects on their proliferation].
Topics: Adenocarcinoma; Animals; Carbazilquinone; Cell Division; Drug Screening Assays, Antitumor; Estradiol; Etoposide; Female; Humans; Methotrexate; Mice; Mitomycin; Neoplasm Transplantation; Progesterone; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1992 |
Combination chemotherapy tested in a short-term thymidine incorporation assay in primary cultures of ovarian adenocarcinomas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Ovarian Neoplasms; Thymidine; Tumor Cells, Cultured | 1992 |
Case report: cisplatin-induced hemolytic uremic syndrome.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carcinoma, Small Cell; Cisplatin; Etoposide; Hemolytic-Uremic Syndrome; Humans; Lung Neoplasms; Male; Middle Aged; Spinal Neoplasms | 1991 |
Clinical pharmacology and toxicity of low daily administration of oral etoposide in advanced lung cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1991 |
Carcinoma of unknown primary: identification of a treatable subset?
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Etoposide; Female; Humans; Male; Middle Aged; Neoplasms, Unknown Primary | 1990 |
Pancreatoblastoma: response to chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Dactinomycin; Doxorubicin; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Lymphatic Metastasis; Male; Pancreatic Neoplasms; Vinblastine; Vincristine | 1991 |
Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
Topics: Adenocarcinoma; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Cell Line; Colonic Neoplasms; DNA; DNA Damage; DNA Probes; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Etoposide; Humans; Immunoblotting; Lung Neoplasms; Membrane Glycoproteins; Molecular Sequence Data; Neoplasm Proteins; Porfiromycin; RNA; Teniposide | 1991 |
[Thermochemotherapy of prostatic cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bleomycin; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Evaluation Studies as Topic; Humans; Hyperthermia, Induced; Male; Middle Aged; Peplomycin; Prostatic Neoplasms | 1991 |
Pancreatic adenocarcinoma responding to cisplatin based cytotoxic chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Etoposide; Humans; Male; Middle Aged; Pancreatic Neoplasms | 1991 |
Cisplatin and etoposide in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Evaluation; Etoposide; Female; Humans; Male; Middle Aged; Remission Induction | 1991 |
[5'-deoxy-5-fluorouridine (5'-DFUR), mitomycin C (MMC), etoposide and medroxy progesterone acetate (MPA) in a previously treated patient with advanced breast cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Etoposide; Female; Floxuridine; Humans; Liver Neoplasms; Lymphatic Metastasis; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Mitomycin; Mitomycins; Remission Induction | 1991 |
Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prognosis; Regression Analysis; Survival Analysis | 1991 |
Etoposide and mitomycin in the treatment of non-small-cell lung cancer. A phase I-II evaluation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Mitomycins; Remission Induction; Survival Rate; Time Factors | 1991 |
[The efficacy and side effects of chemotherapy for primary lung cancer with cisplatin and etoposide].
Topics: Adenocarcinoma; Administration, Oral; Angina Pectoris; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Humans; Infusions, Intravenous; Kidney; Leukopenia; Lung Neoplasms | 1991 |
Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Stomach Neoplasms; Survival Analysis | 1991 |
[Combination chemotherapy with cisplatin and etoposide for cerebellar metastasis from ovarian adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Cisplatin; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Remission Induction | 1991 |
Weekly etoposide, methotrexate and actinomycin D, alternating with cyclophosphamide plus vincristine (EMA/CO): a phase II study in advanced gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Drug Evaluation; Etoposide; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Staging; Remission Induction; Stomach Neoplasms; Vincristine | 1991 |
Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.
Topics: Adenocarcinoma; Colonic Neoplasms; DNA Damage; DNA Repair; DNA, Neoplasm; Etoposide; Gene Amplification; Genes, myc; Humans; Leukemia, Promyelocytic, Acute; Teniposide; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1991 |
The effectiveness of a combination of etoposide/adriamycin/cisplatin (EAP) against inoperable gastric cancer--report of a histologically proven case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Stomach Neoplasms | 1991 |
[Antitumor activity by long-term administration of low-dose etoposide].
Topics: Adenocarcinoma; Administration, Oral; Animals; Colonic Neoplasms; Etoposide; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL | 1991 |
Differential in vitro sensitivity of human tumor and normal cells to chemotherapeutic agents and resistance modulators.
Topics: Adenocarcinoma; Antineoplastic Agents; Buthionine Sulfoximine; Cell Division; Cell Line; Cell Survival; Cisplatin; Cyclosporins; Doxorubicin; Drug Screening Assays, Antitumor; Etoposide; Humans; Kidney Neoplasms; Kinetics; Leukemia; Lymphocytes; Methionine Sulfoximine; Neurilemmoma; Tumor Cells, Cultured; Verapamil; Vincristine | 1991 |
Phase II studies with carboplatin in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Remission Induction; Survival Rate | 1990 |
[Acute myocardial infarction induced by lung cancer chemotherapy with cisplatin and etoposide].
Topics: Adenocarcinoma; Aged; Carcinoma, Small Cell; Cisplatin; Electrocardiography; Etoposide; Humans; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction | 1990 |
Infusion of high doses of undiluted etoposide through central venous catheters during preparation for bone marrow transplantation.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Bone Marrow Transplantation; Carcinoma, Non-Small-Cell Lung; Catheterization, Central Venous; Colonic Neoplasms; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Middle Aged; Neoplasms | 1990 |
Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Rate | 1990 |
Phase II trial of etoposide, doxorubicin (Adriamycin), and cisplatin (EAP regimen) in advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Evaluation; Etoposide; Female; Gastrectomy; Humans; Male; Middle Aged; Neutropenia; Stomach Neoplasms; Thrombocytopenia | 1990 |
A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Drug Evaluation; Etoposide; Female; Fluorouracil; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Remission Induction; Thrombocytopenia | 1990 |
[Study on etoposide therapy of relapsing prostatic cancer patients].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Drug Administration Schedule; Drug Evaluation; Etoposide; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Prostatic Neoplasms | 1990 |
Pharmacokinetics of very high-dose oral melphalan in cancer patients.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Bone Marrow Transplantation; Carmustine; Etoposide; Female; Humans; Injections, Intravenous; Lymphoma; Male; Melanoma; Melphalan; Middle Aged; Time Factors | 1990 |
A phase II study of the combination of etoposide and cisplatin in the therapy of advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Remission Induction; Stomach Neoplasms | 1990 |
Locally advanced unresectable gastric cancer successfully resected after neoadjuvant chemotherapy with FADE regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; Etoposide; Fluorouracil; Humans; Male; Middle Aged; Stomach; Stomach Neoplasms; Tomography, X-Ray Computed | 1990 |
Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagogastric Junction; Etoposide; Female; Fluorouracil; Humans; Male; Middle Aged; Survival Analysis; Time Factors | 1990 |
[A case of stage III ovarian carcinoma successfully treated with oral etoposide].
Topics: Adenocarcinoma; Administration, Oral; Combined Modality Therapy; Drug Administration Schedule; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Reoperation | 1990 |
Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Time Factors | 1985 |
[The relationship between morphological manifestations and cell kinetic changes of human lung cancer cells after exposure to chemotherapeutic agents].
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Cycle; Cell Line; Cisplatin; DNA, Neoplasm; Etoposide; Flow Cytometry; Humans; Lung Neoplasms; Peplomycin | 1986 |
[Combination chemotherapy with UFT, etoposide, CDDP, adriamycin (FEPA) in advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Gastrectomy; Humans; Leukopenia; Male; Middle Aged; Remission Induction; Stomach Neoplasms; Survival Rate; Tegafur; Uracil | 1989 |
[Combination with medroxyprogesterone acetate and chemotherapy making possible complete removal of uterine corpus carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Etoposide; Female; Humans; Hysterectomy; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Remission Induction; Reoperation; Uterine Neoplasms | 1989 |
A phase I/II trial of 5-fluorouracil and etoposide in metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluation; Drug Synergism; Etoposide; Female; Fluorouracil; Humans; Male; Middle Aged | 1989 |
[Combination therapy with etoposide, adriamycin and cisplatin in advanced primary and recurrent gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Evaluation; Etoposide; Female; Humans; Leukopenia; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Remission Induction; Stomach Neoplasms; Thrombocytopenia; Vomiting | 1989 |
[The course of squamous cell carcinoma antigen and CEA as prognostic criteria for response to chemotherapy in cervix cancer].
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoembryonic Antigen; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Humans; Ifosfamide; Neoplasm Recurrence, Local; Organoplatinum Compounds; Prognosis; Serpins; Uterine Cervical Neoplasms | 1989 |
[A multimodal treatment of prostatic carcinoma and the 5-year survival rate].
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Drug Administration Schedule; Estrogens; Etoposide; Humans; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Prostatic Neoplasms | 1989 |
Resolution of malignant small bowel obstruction after intraperitoneal etoposide therapy.
Topics: Abdominal Neoplasms; Adenocarcinoma; Etoposide; Humans; Infusions, Parenteral; Intestinal Obstruction; Intestine, Small; Lung Neoplasms; Male; Middle Aged | 1989 |
Enhancement of the in vitro and in vivo antitumor activities of phosphorylated mitomycin C and etoposide derivatives by monoclonal antibody-alkaline phosphatase conjugates.
Topics: Adenocarcinoma; Alkaline Phosphatase; Animals; Antibodies, Monoclonal; Biotransformation; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Mitomycins; Neoplasm Transplantation; Organophosphorus Compounds; Transplantation, Heterologous; Tumor Cells, Cultured | 1989 |
Etoposide, ifosfamide, and cisplatin in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Humans; Ifosfamide; Lung Neoplasms; Middle Aged | 1987 |
Preoperative combined modality therapy for stage III M0 non-small cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Etoposide; Female; Fluorouracil; Humans; Lung Neoplasms; Male; Middle Aged | 1988 |
Pilot study of a continuous five-day intravenous infusion of etoposide concomitant with cisplatin in selected patients with advanced cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Histiocytoma, Benign Fibrous; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Stomach Neoplasms; Tongue Neoplasms | 1988 |
[FEP and FAP combination chemotherapy in advanced gastric cancer. Research Group for Gastric Cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Male; Middle Aged; Stomach Neoplasms; Tegafur; Uracil | 1988 |
[Chemotherapy of non-small cell bronchial cancer with ifosfamide in combination with cisplatin, etoposide or vindesine].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Vindesine | 1988 |
Over-expression of MDR1 gene with no DNA amplification in a multiple-drug-resistant human ovarian carcinoma cell line.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chromosome Deletion; Dactinomycin; Doxorubicin; Drug Resistance; Etoposide; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Phenotype; Tumor Cells, Cultured; Verapamil; Vincristine | 1989 |
[Treatment of non-small-cell bronchial carcinoma with cisplatin, ifosfamide, vindesine and VP 16].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vindesine | 1985 |
[A phase II study of oral VP-16 in primary lung cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Capsules; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Podophyllotoxin | 1985 |
[A phase II study of NK171 (etoposide)].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Anorexia; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Infusions, Parenteral; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Podophyllotoxin | 1985 |
[A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Anorexia; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Injections; Lung Neoplasms; Male; Middle Aged; Nausea; Podophyllotoxin | 1986 |
[Phase II study of etoposide in patients with lung cancer, with special reference to small cell carcinoma].
Topics: Adenocarcinoma; Aged; Carcinoma, Small Cell; Drug Administration Schedule; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Podophyllotoxin | 1986 |
[Combination chemotherapy with etoposide, mitomycin C, and cyclophosphamide in advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Mitomycins | 1986 |
Cisplatin, etoposide, and mitomycin in the treatment of non-small cell carcinoma of the lung. A pilot study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Humans; Lung Neoplasms; Middle Aged; Mitomycins; Pilot Projects | 1986 |
DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
Topics: Adenocarcinoma; Adenosine Triphosphate; Carcinoma, Small Cell; Cell Division; Cell Nucleus; Cells, Cultured; DNA; DNA, Single-Stranded; Drug Resistance; Etoposide; Humans; Intercalating Agents; Lung Neoplasms; Podophyllotoxin; Teniposide; Topoisomerase II Inhibitors | 1986 |
Experience with ifosfamide combinations (etoposide or DDP) in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged | 1986 |
Antitumor effect of two-drug simultaneous or sequential use of cisplatin, vindesine or etoposide on human pulmonary adenocarcinoma cell lines in tumor clonogenic assay.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cisplatin; Colony-Forming Units Assay; Etoposide; Humans; Lung Neoplasms; Tumor Stem Cell Assay; Vindesine | 1986 |
[A case of gastric carcinoma remarkably responding to etoposide, adriamycin and cisplatin (EAP) therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Duodenal Ulcer; Etoposide; Gastrectomy; Humans; Male; Middle Aged; Stomach Neoplasms | 1988 |
Treatment of brain metastases of lung cancer with high doses of etoposide (VP16-213). Cooperative study from the Groupe Franais Pneumo-Cancérologie.
Topics: Adenocarcinoma; Aged; Brain; Brain Neoplasms; Carcinoma; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Tomography, X-Ray Computed | 1988 |
[A case of recurrent ovarian cancer successfully treated with etoposide].
Topics: Adenocarcinoma; Administration, Oral; Combined Modality Therapy; Etoposide; Female; Humans; Middle Aged; Ovarian Neoplasms; Pelvic Neoplasms; Reoperation | 1988 |
Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Lung Neoplasms; Male; Methotrexate; Middle Aged; Mitomycin; Mitomycins; Neoplasm Metastasis; Procarbazine; Progesterone; Prognosis; Serum Albumin; Vinblastine | 1986 |
Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged | 1986 |
[A case of coexisting primary malignant lymphoma and adenocarcinoma of the stomach].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Gastrectomy; Gastroscopy; Humans; Lymphoma; Neoplasms, Multiple Primary; Prednisolone; Stomach; Stomach Neoplasms; Vinblastine; Vincristine | 1986 |
Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease.
Topics: Adenocarcinoma; Cell Line; Drug Evaluation; Drug Resistance; Etoposide; Hormones; Humans; Male; Prostatic Neoplasms; Tumor Stem Cell Assay | 1986 |
"Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma".
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 1986 |
Phase II trial of cisplatin and etoposide in adenocarcinomas of the upper gastrointestinal tract.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms | 1987 |
Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide.
Topics: Adenocarcinoma; Aminoacridines; Amsacrine; Cells, Cultured; DNA; DNA Repair; Etoposide; Humans; Lung Neoplasms; Podophyllotoxin; Teniposide | 1985 |
Combination chemotherapy with vindesine, etoposide, and cisplatin in non-small cell lung cancer: a pilot study of the Southeastern Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma; Carcinoma, Squamous Cell; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Vindesine | 1986 |
[Effect of etoposide for urogenital tumors].
Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Etoposide; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Pancreatic Neoplasms; Podophyllotoxin; Prostatic Neoplasms; Rhabdomyosarcoma; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urogenital Neoplasms | 1985 |
Synchronous presentation of two primary bronchogenic carcinomas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Combined Modality Therapy; Cyclophosphamide; Etoposide; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Radiography, Thoracic; Vincristine | 1985 |
[The antitumor activity of intraperitoneally- or orally-administered etoposide in animals and its administration-schedule dependency].
Topics: Adenocarcinoma; Administration, Oral; Animals; Carcinoma, Ehrlich Tumor; Colonic Neoplasms; Drug Administration Schedule; Etoposide; Female; Leukemia, Experimental; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Mice; Neoplasms, Experimental; Podophyllotoxin | 1985 |